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CHAPTER 1: Background 
I. Introduction 
It is well documented that sex differences exist in the susceptibility to cardiovascular 
disease.  Prior to menopause, the incidence of cardiovascular disease is lower in age-matched 
females than in males (Barrett-Connor et al. 1997; Crabbe et al. 2003; Hayward et al. 2001).  
Following completion of menopause, the risk of developing cardiovascular disease in females 
increases dramatically (Hayward et al. 2001).  Additionally, it has been demonstrated that 
females suffering from cardiovascular disease show reduced responsiveness to typical 
interventions than males, and greater likelihood of developing heart failure after suffering a 
myocardial infarction (Xhyheri et al. 2010; Huxley 2007).  A role for sex steroid hormones in 
modulating cardiovascular function has been demonstrated in several species (including humans), 
in both normal and pathological states.  In spite of these observations, the majority of 
cardiovascular research is still performed only in males (Leinwand 2003).  
β-adrenergic receptors are central mediators of cardiovascular function, making them key 
pharmaceutical targets in the treatment of cardiovascular disease (CVD).  It has been 
demonstrated in ventricular myocytes and left atrial tissue that males show enhanced contractile 
responsiveness to β-adrenergic receptor stimulation as compared to females (Curl et al. 2001; 
Schwertz et al. 1999; Vizgirda et al. 2002).  In contrast, other groups in muscle strip models have 
not seen these differences (Chu et al. 2005; Monasky et al. 2008).  However, whether sex 
differences exist in β-adrenergic responsiveness in intact myocardium, as well what the potential 
mechanisms for these differences could be has not been fully elucidated.  Therefore, the first aim 
of this study was to determine the contractile response to β-adrenergic receptor stimulation in the 
isolated perfused heart using age-matched male and female mice, and address potential 
mechanisms for any observed sex differences in the intact heart.  The second aim of this study 
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was to address potential mechanisms for sex differences in the β-adrenergic contractile response 
using adult ventricular myocytes.  Uncovering the mechanism for sex differences in the β-
adrenergic receptor contractile response may enable enhanced, sex-specific pharmaceutical 
treatments for cardiovascular disease. 
II. β-Adrenergic Receptors in the Heart 
The β-adrenergic receptors belong to the family of 7 transmembrane G protein-coupled 
receptors (GPCR), of which there are three subtypes: β1, β2 and β3.  The β-adrenergic receptors 
are highly conserved across species, from mouse to human.  Stimulation of cardiac β-adrenergic 
receptors by norepinephrine (released by sympathetic nerve terminals) results in an increased 
heart rate (positive chronotropy), increased force of contraction (positive inotropy) and increased 
rate of relaxation (positive lusitropy).  The positive chronotropic, inotropic, and lusitropic effects 
of β-adrenergic receptor stimulation are mediated primarily by the β1 adrenergic receptor and to 
lesser extent the β2 adrenergic receptor (Rohrer et al. 1999; Chrusinski et al. 1999).   
The β1-adrenergic receptor (β1R) is coupled to Gsα protein, and stimulates increases in 
contractility via the adenylyl cyclase-cAMP-protein kinase A signaling pathway.  The β2-
adrenergic receptor (β2R) is expressed in significantly lower levels than the β1R.  The ratio of 
β1R to β2R is approximately 70-80:20-30 β1R to β2R in human ventricle (Brodde 1991), and 
approximately 75:25 in mouse myocytes (Zhu et al. 2005).  The β2R can couple to both Gsα and 
Giα proteins on ventricular myocytes (Xaio et al. 1995), and can therefore stimulate or inhibit 
cAMP-mediated signaling depending on the coupling status of the receptor.  
The positive lusitropic and intropic states of the myocyte elicited by β-adrenergic 
receptor stimulation are ultimately determined by the degree of phosphorylation of troponin I 
(TnI), phospholamban (PLB), the ryanodine receptor (RyR) and the L-type calcium channel 
(Xiang et al. 2003).  Phosphorylation of TnI at serine 23/24 by cAMP-dependent protein kinase 
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(PKA) results in a reduced affinity of the troponin complex for calcium, enhancing the rate of 
relaxation of the myocyte (Pi et al. 2002).  PLB negatively regulates the 
sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA), the calcium reuptake channel 
on the SR.  Phosphorylation of PLB at residue serine 16 reduces its inhibition of SERCA, 
allowing enhanced calcium uptake into the sarcoplasmic reticulum (SR) and enabling enhanced 
rates of myocyte relaxation (Chu et al. 2000). The RyR is the calcium release channel on the 
sarcoplasmic reticulum.  It has been speculated that phosphorylation of the RyR at serine 2808 
by PKA increases the probability of the RyR being open (Shan et al. 2010), enabling enhanced 
calcium availability for contraction.  The L-type calcium channel on the sarcolemma allows 
calcium movement into the cell during the myocyte action potential, resulting in calcium-
induced release of SR calcium.  Phosphorylation of this channel (Hulme et al. 2006) also 
increases the amount of calcium than may enter the cell.  This signaling pathway is shown in 
Figure 1. 
Adenylyl
Cyclase
Gsα
β1R
ATP cAMP
AMP
PKA
β2R
Gsα
Giα
PDE
-
++
TnI
PLB RyR
LTCC PP1, PP2A
A1AR
Giα
 
Figure 1- β-adrenergic receptor signaling pathway. β1R- β1-adrenergic receptor, β2R- β2-
adrenergic receptor, A1AR- A1 adenosine receptor, PDE- phosphodiesterase, PKA- protein 
kinase a, TnI- troponin I, PLB- Phospholamban, RyR- ryanodine receptor, LTCC- L-type 
calcium channel, PP1- protein phosphatase 1, PP2A- protein phosphatase 2A. 
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Note in Figure 1 that cAMP levels in the cell are modulated by 3’,5’-cyclic nucleotide 
phosphodiesterase (PDE) enzymes, which convert cAMP to 5’-AMP (as well as cGMP to 5’-
GMP).  Phosphodiesterases regulate basal cAMP levels as well as cAMP levels during β-
adrenergic receptor stimulation.  There are 11 known families of PDEs, and at least four cAMP-
hydrolyzing PDE families have been shown to be expressed in the heart: PDE1, PDE2, PDE3 
and PDE4 (Pang 1992).  PDE4 is phosphorylated and activated by PKA, and appears to be the 
primary isoform involved in modulation of the β-adrenergic contractile response (De Arcangelis 
et al. 2008; Mongillo et al. 2004; Perry et al. 2002; Richter et al. 2008; Xiang et al. 2005).   
Also involved in the modulation of β-adrenergic receptor signaling are protein 
phosphatases, enzymes that remove phosphate groups from the aforementioned target proteins.  
Protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A) are both serine/threonine 
phosphatases that account for more than 90% of dephosphorylation reactions in mammalian cells 
(Herzig et al. 2000).  Both forms of protein phosphatases have been shown to modulate 
phosphorylation states of phospholamban, troponin I, etc (Liu et al. 2002; MacDougall et al. 
1991).  βR stimulation results in reduced protein phosphatase 1 activity, via activation of protein 
phosphatase inhibitor-1 (Neumann et al.  1991). Protein phosphatases and phosphodiesterases are 
both part of an intrinsic regulatory system in myocytes, preventing extreme contractile responses 
elicited by β-adrenergic receptor activation.   
III. Modulation of β-Adrenergic Receptor Function by Adenosine Receptors 
Adenosine is an autocoid which is produced through the hydrolysis of 5’AMP by 5’-
nucleotidase.  Levels of adenosine consequently increase during conditions in which ATP 
breakdown is increased, such as during β-adrenergic receptor stimulation (Manfredi et al. 1982; 
Saito et al. 1980; Wiedmeier et al. 1977).  Adenosine exerts its effects through binding to G 
protein-coupled adenosine receptors (AR), which play roles in both modulation of normal 
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cardiovascular function and promotion of cardioprotection.  There is evidence for the expression 
of all four adenosine receptors (A1, A2a, A2b and A3) in the heart, though only the expression of 
the A1 adenosine receptor (A1AR) in the cardiac myocyte has been confirmed using radioligand 
binding (Martens et al. 1988).  Activation of the A1AR on sinoatrial and atrioventricular nodal 
tissue has a dramatic negative chronotropic effect.  Additionally, activation of both A2aAR and 
A2bAR on vascular tissue results in potent vasodilation.  Both A1AR and A2aAR have a high 
affinity for the endogenous ligand adenosine, while the A2bAR has a low affinity for adenosine.   
The A1AR couples to Giα protein and limits the positive inotropic effects of β-adrenergic 
receptor stimulation (the so-called “anti-adrenergic effect”).  Multiple models have demonstrated 
that pre-treatment with an A1AR agonist results in reduced contractile responses to βR agonist 
treatment (Belardinelli et al. 1983; Brown et al. 1990; Perlini et al. 1998; Richardt et al. 1989).  
Additionally, pharmacological inhibition of the A1AR has been shown to potentiate the 
contractile effect of βR stimulation, suggesting there is a role for endogenous adenosine in 
regulating the normal β-adrenergic contractile response (Dobson et al. 1986; Dobson et al. 1996).  
While the A2aAR does not alter β-adrenergic receptor function directly, both pharmacological 
inhibition and genetic deletion of the A2aAR has been shown to enhance the anti-adrenergic 
effect of the A1 adenosine receptor in the isolated heart (Chandrasekera et al.  2010; Norton et al. 
1999). 
IV. Sex Differences in the Cardiovascular System 
Multiple investigators have demonstrated that sex differences exist both in the normal 
cardiovascular system and in susceptibility to cardiovascular disease.  Some of these differences 
are shown in Table 1 (summarized from Virginia Huxley Refresher Course, Advances in 
Physiology Education, 2007).  
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Table 1- Sex differences in the human cardiovascular system 
Sex Difference Reference 
Anatomy 
Greater ventricular mass in males De Simone et al. 1991; 
Hammond et al. 1988; 
Levy et al. 1987 
Greater major vessel size in males Vasan et al. 1997 
Electrophysiology 
Higher heart rate in females than males Umentani et al. 1998 
Longer QT interval in females than males Surawicz et al. 2003 
Lower expression of some subclasses of potassium channels 
involved in repolarization in females 
Gaborit et al. 2010 
Autonomic Control 
Response to cardiovascular stress: males tend to increase total 
peripheral resistance and females tend to increase heart rate 
Barnett et al. 1999 
Lower sympathetic activity, enhanced parasympathetic activity in 
females; higher plasma norepinephrine in older males 
Geelen et al. 2002 
Pathology 
Susceptibility to hypertension greater in males Messerli  et al. 1987 
Reduced susceptibility to heart failure in general population in 
females 
Gottdiener et al. 2000 
Susceptibility to heart failure following MI greater in females Tofler et al.  1987 
Acute myocardial infarct symptoms differ between males and 
females 
Chen et al. 2005 
 As shown in Table 1, it is well-documented that sex differences are present in multiple 
cells types in the human heart, including conductive tissue, vascular tissue, and myocytes.  Sex 
differences in the cardiovascular system have also been demonstrated in other species (canine, 
rabbit, guinea pig, rat mouse, etc). 
 The sex differences of interest to this project relate to primarily to ventricular myocytes 
and calcium regulation.  Several groups have demonstrated in rodent models that females display 
greater basal L-type calcium channel current (Vizgirda et al. 2002; Xiao et al. 2006) though 
others have shown no such differences (Kennedy et al. 2003; Sun et al. 2006).  Additionally, it 
has been demonstrated in both myocyte (Curl et al. 2001; Farrell et al. 2010; Petre et al. 2007; 
Wasserstrom et al. 2008) and papillary muscle (Curl et al. 2008; Leblanc et al. 1998) that males 
show greater basal contractile amplitude than females.  Farrell and colleagues recently published 
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that sex differences exist in excitation-contraction coupling gain (i.e. calcium flux per unit ICaL), 
with females showing significantly lower gain as compared to males (Farrell et al. 2010).  If 
these differences exist in the basal state, there are likely ramifications in terms of both enhanced 
stimulation by βR as well as under pathological conditions.   
V. Sex Differences in Cardiac Gene Expression 
The role of sex steroid hormones in modulating gene expression is commonly addressed 
as a potential mechanism for the presence of sex differences exist in the cardiovascular system.  
The classical function of both estrogen and testosterone is to modulate gene transcription, 
accomplished through binding to their nuclear receptors (estrogen receptor alpha and beta, and 
androgen receptor, respectively).  There is evidence for the expression of both nuclear estrogen 
receptor subtypes (Grohé et al. 1997), as well as the nuclear androgen receptor (Marsh et al. 
1998) in cardiac myocytes.  Expression of these receptors in vascular tissue has also been 
demonstrated (Barton et al. 2007; Hodges et al. 2000; Liu et al. 2005). 
Sex differences in the expression of many genes coding for proteins involved in 
cardiovascular function have been demonstrated.  For example, Gaborit and colleagues found 
that non-diseased human female hearts show reduced gene and protein expression of many K+ 
channel subunits (Gaborit et al. 2010), and this has also been shown in murine myocardium 
(Saito et al. 2009).  Isensee and colleagues performed a thorough analysis of sexually dimorphic 
gene expression in both young and aged mouse myocardium, as well as human myocardium, and 
found numerous genes involved in cellular processes such as signaling, growth, regulation, stress 
responses, etc. to be different in expression between male and female (Isensee et al. 2008).  Chu 
and colleagues found gene and protein expression of the sodium-calcium exchanger (NCX) and 
ryanodine receptor to be higher in females than males, and also found that Cav1.2 (a subunit of 
the L-type calcium channel) protein expression was higher in females (though Cav1.2 gene 
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expression was higher in males) (Chu et al. 2005).   
Along with modulating gene expression, sex steroids have also been shown to act on a 
more acute time-scale by activating cellular signaling cascades.  There are reports that estrogen 
can bind to both translocated nuclear estrogen receptors and the G protein-coupled receptor 
GPR30 at the plasma membrane and activate the phosphoinositide 3-kinase-Akt signaling 
cascade (Revankar et al. 2005), a signaling pathway implicated in cardioprotection.  Both 
estrogen and testosterone have been shown to alter intracellular calcium acutely, independent of 
effects on transcription (Buitrago et al. 2000; Er et al. 2007).  Estrogen and testosterone also 
have effects on vascular tone, presumably non-genomic and more likely related to these changes 
in intracellular calcium. 
VI. Impact of Sex Steroid Hormone Withdrawal on Gene Expression and Cardiac Function 
The increased risk of developing cardiovascular disease following menopause provides 
more evidence for the role played by ovarian hormones in the cardiovascular system.  The 
impact of ovarian hormones (estrogen and progesterone) on cardiovascular function is 
commonly addressed using the ovariectomy model.  Ovarian hormone withdrawal in females has 
been shown to change the expression of L-type calcium channel and the sodium-calcium 
exchanger (Chu et al. 2006).  Additionally, functional consequences of ovarian hormone 
withdrawal have been demonstrated.  Ma and colleagues showed that rat ventricular myocytes 
from ovariectomized females display greater resting calcium levels and greater amplitudes of 
calcium transients than myocytes from intact females (Ma et al. 2009).  Greater calcium channel 
activity has been observed in ovariectomized as compared to intact female myocytes, as well as 
greater basal PKA activity in ovariectomized female myocytes (Kam et al. 2005).  Patterson and 
colleagues documented increased LTCC density in rabbit myocardium from ovariectomized 
females (Patterson et al. 1998).  Reduced peak shortening and velocities of shortening and 
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relenghtening were observed in myocytes from ovariectomized female mice as compared to 
intact female mice (Ren et al. 2003). 
Testosterone withdrawal via castration has also been shown to change the expression of 
genes involved in calcium regulation: Golden and colleagues demonstrated that cardiac tissue 
from castrated males expressed lower levels of the L-type calcium channel genes and 
dramatically lower levels of NCX than intact males (Golden et al. 2002).  In a subsequent study 
they demonstrated that testosterone withdrawal increased the time to peak shortening and 
relengthening in myocytes (Golden et al. 2003). 
VII. Sex Differences in β-Adrenergic Receptors 
As noted previously, multiple reports suggest that myocytes from females display 
reduced β-adrenergic contractile responsiveness to the non-selective β-adrenergic receptor 
agonist isoproterenol (ISO) as compared to myocytes from males (Curl et al. 2001; Vizgirda et al. 
2002), a finding which was also demonstrated in left atrial tissue (Schwertz et al. 1999).  In 
contrast, other groups using muscle strip models have shown no such differences (Chu et al. 
2005; Monasky et al. 2008).  Additional inconsistencies exist in the literature regarding the 
mechanism for sex differences in the β-adrenergic contractile response.  Some have proposed 
that females show reduced expression of βR (Vizgirda et al. 2002), and that sex differences exist 
in calcium regulation upon βR stimulation (Chen et al. 2003; Curl et al. 2001; Curl et al. 2008; 
Vizgirda et al. 2002).  For example, Chen and colleagues have demonstrated that sex differences 
in ischemia/reperfusion injury only manifest themselves if hearts are also exposed to 
isoproterenol, with females showing less injury than males in this condition (Chen et al. 2003).  
However, a thorough investigation into cardiac β-adrenergic receptor function and signaling in 
both males and females has not been conducted. 
Multiple groups have shown that ovarian hormone withdrawal (via ovariectomy) results 
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in increased expression of the β1R in rat cardiac tissue (Chu et al. 2006; Thawornkaiwong et al. 
2003).  Treatment of ovariectomized rats with estrogen and progesterone has been shown to 
increase β-adrenergic receptor density but decrease receptor binding in cardiac tissue 
(Klangkalya et al. 1988).  In spite of β-adrenergic receptor upregulation in ventricular tissue, Chu 
and colleagues saw no functional difference in the contractile response to receptor stimulation in 
right ventricular papillary muscle strips between intact and ovariectomized females (Chu et al. 
2006).  This has also been observed in rabbit papillary muscle (Patterson et al. 1998).  In contrast, 
Kam and colleagues found that ovariectomized rat female myocytes displayed enhanced PKA 
and L-type calcium channel activity responses to isoprenaline treatment as compared to intact 
female myocytes.  They also found enhanced contractile responses to isoprenaline in an isolated 
rat heart model in ovariectomized as compared to intact females (Kam et al. 2005).   
Sex differences in βR signaling, or modulation of βR signaling by phosphodiesterases or 
protein phosphatases, has not been addressed in the literature.  While multiple groups have 
demonstrated that contractile differences exist in male and female ventricular myocytes 
stimulated with isoproterenol, there are no known studies that compared the βR signaling 
cascade in males and females.  
Sex Differences in Adenosine Receptors 
 As previously mentioned, A1 adenosine receptors exert a potent anti-adrenergic effect on 
the contractile response to βR stimulation.  The role of A1AR in differentially modulating the βR 
response in males and females has never been investigated.  Furthermore, little research has been 
done to investigate sex differences in adenosine receptors.  One report indicates that there are no 
gender differences in A1AR and A3AR gene expression in mouse hippocampus (von Armin et al. 
2002).  Ovariectomy and estrogen replacement has been shown to modulate adenosine receptor 
gene expression in both rat and mouse brain (Ribeiro et al. 2009; Rose’Meyer et al. 2003).  
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However, there are no reports on sex differences in cardiac adenosine receptor expression.  
Additionally, little research has been done on sex differences in cardiac adenosine receptor 
function.  In two reports, Yang and colleagues noted that genetic deletion of the A1AR in females 
had little effect on heart rate, whereas males showed increases in heart rate following A1AR 
deletion (Yang et al. 2009; Yang et al. 2007).   
VIII. β-Adrenergic Receptors as Pharmaceutical Targets 
 The genome codes for approximately 350 G protein-coupled receptors that detect 
hormones, growth factors and other endogenous ligands (Vassilatis et al. 2003), and these 
receptors are the targets of approximately 30% of current pharmaceutical treatments (Overington 
et al. 2006).  Included in these targets are the β-adrenergic receptors, as β- adrenergic receptor 
antagonists (“beta-blockers”) are commonly prescribed to prevent or treat hypertension, stroke, 
and other cardiovascular conditions.  Interestingly, Lujan and colleagues demonstrated that 
females have a greater ventricular arrhythmia threshold (VAT) than males during coronary artery 
occlusion in conscious rats, and that βR blockade only prolonged VAT in males (Lujan et al. 
2008).  Additionally, while there were no differences in incidence of ventricular tachycardia 
(VT) following coronary artery occlusion and reperfusion between males and females, βR 
blockade reduced the incidence of VT only in females (Lujan et al. 2007). 
 Although multiple groups have shown that sex differences exist in β-adrenergic receptor 
expression and function, and that changes in βR expression and function occur following ovarian 
hormone withdrawal, there are currently no guidelines for treating males and females with CVD 
differently using β-adrenergic receptor blockers.  Interestingly, it has been demonstrated that 
females show greater morbidity and mortality following diagnosis of cardiovascular disease than 
males, suggesting that there is precedence for differentially treating the sexes (Kannel et al. 
1995; Tofler et al. 1987).  Elucidation of the mechanism for sex differences in β-adrenergic 
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receptor signaling may enable the development of enhanced, specialized pharmaceutical 
treatments for cardiovascular disease in males and females, as well as pre- versus post-
menopausal females. 
IX. Summary and Hypothesis 
 Males and females display numerous differences in cardiovascular function, including at 
the level of the myocardium.  While this has been well-documented, the majority of 
cardiovascular research is still performed only in males.  Sex differences in the contractile 
response to stimulation of a key receptor family in the myocardium, the β-adrenergic receptors, 
have been demonstrated in ventricular myocytes.  However, this has not been shown in an intact 
heart, nor has a mechanism for these differences been elucidated.  Therefore, the following is the 
primary hypothesis of this dissertation: 
 Hypothesis 1: Females show reduced β-adrenergic contractile responsiveness in the 
isolated perfused heart.   
 While basic mechanisms such as calcium regulation following βR stimulation have been 
considered to address reduced βR responsiveness in females, a robust analysis of βR signaling in 
myocardial or ventricular myocyte tissue has not been performed to date.  A secondary 
hypothesis of this dissertation was established to address this deficiency: 
 Hypothesis 2: Females show altered function or expression of components of the β-
adrenergic receptor signaling pathway relative to males, which contributes to their reduced 
contractile responsiveness to β-adrenergic receptor stimulation. 
 The role of ovarian hormones in generating an altered β-adrenergic response was 
considered as well, using ovariectomized female mice. 
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Chapter 2: β-Adrenergic Contractile Response in Males, Intact Females and 
Ovariectomized Females- Methods and Results 
I. Rationale 
The first hypothesis of this study was that females would show a reduced contractile 
response to βR stimulation as compared to males.  This prediction was based on a thorough 
survey of the literature, in which the majority of investigators have documented this sex 
difference in myocytes.  However, isolated myocyte studies are limited, as cells are typically 
maintained at un-physiologically low temperatures and paced at extremely low rates for these 
studies.  This question had not been addressed in a more physiological model such as the intact 
heart, maintained at 37°C and beating at 420 beats per minute. 
These studies were also performed in hearts from female mice that were ovariectomized.  
This was done in order to determine if ovarian hormones play a role in generating sex differences 
in the β-adrenergic contractile response.  Ovarian hormone withdrawal, such as that which 
occurs during menopause, has important physiological consequences which were discussed in 
the Background.  These studies could provide insight into the role of ovarian hormones in 
modulation of the β-adrenergic contractile response.  A thorough survey of the literature was 
performed on this topic, and it was predicted that the contractile response would be enhanced in 
ovariectomized mice as compared to intact female mice. 
II. Materials 
Deionized, distilled water was purchased from Lonza (Basel, Switzerland).  Isoproterenol 
(ISO), NaCl, KCl, KH2PO4, MgSO4, NaHCO3, CaCl2, Glucose, Sodium Pyruvate and EDTA were 
purchased from Sigma-Aldrich, Inc (St Louis, MO).  ISO was prepared as a 10 mM stock 
solution in phosphate buffered saline with 0.1% sodium metabisulfite. 
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III. Methods 
A. Animal Model  
The animals in this study were maintained and used in accordance with guidelines in the 
Guide for the Care and Use of Laboratory Animals (NIH Publication, No 85-23, Revised 1996) 
and evaluated and approved according to the guidelines of the Institutional Animal Care and Use 
Committee of the Wayne State University School of Medicine.  Ten- to twelve-week old wild-
type C57BL/6 male and female mice were purchased from Jackson Laboratories (Bar Harbor, 
ME).  Additionally, females that were ovariectomized (OvX) at five weeks of age were 
purchased from Jackson Laboratories, and allowed 5-7 weeks for estrogen withdrawal to occur 
prior to study.  Estrogen withdrawal was confirmed by comparing the uterine weight/body 
weight ratio in intact females and ovariectomized females.  Estrus cycle was not monitored in 
intact females. 
B.  Isolated Heart Preparation 
Hearts were excised from anesthetized (sodium pentobarbital, 60 mg/kg) and heparinized 
(500 units) mice, placed in ice-cold saline and mounted on a perfusion apparatus. Hearts were 
perfused at 70 mm Hg with standard Krebs-Henseleit Buffer (KHB)- in mM: NaCl 116, KCl 4.7, 
KH2PO4 1.2, MgSO4 1.2, NaHCO3 24.5, CaCl2 2.0, glucose 11, sodium pyruvate 2.0, EDTA 
0.05.  KHB was filtered using a 0.22 μm in-line filter.  The pH of the KHB was maintained in at 
7.4 by gassing with 95% O2 and 5% CO2.  Temperature was maintained at 37°C with constant-
temperature reservoirs, and by partially submerging the heart into a 37°C water-jacketed 
chamber filled with KHB.  Hearts were paced at 420 beats per minute (bpm) via pacing wires 
inserted into the right ventricle, and a fluid-filled balloon was inserted into the left ventricle (LV) 
across the mitral valve and connected to a pressure transducer, permitting continuous 
measurement of LV pressure.  The fluid-filled balloon was inflated to record a LV diastolic 
15 
 
pressure of 5-8 mmHg.  Ventricular function (LV pressure, +dP/dt and –dP/dt), heart rate (HR), 
coronary flow (CF), and coronary perfusion pressure (CPP) were continuously monitored and 
recorded throughout the experiments (shown in Figure 2, below).  All data were collected and 
analyzed using PowerLab data acquisition systems and LabChart Software for Windows (AD 
Instruments, Inc., Colorado Springs, CO).  
Figure 2- LabChart experiment record, 
baseline tracing. LVP- left ventricular 
pressure; CF- coronary flow; CPP- 
coronary perfusion pressure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
C. β-Adrenergic Contractile Response Protocol 
Hearts were allowed to equilibrate for approximately 20 minutes prior to initiation of the 
experimental protocol.  The working dilution of ISO was added directly to the perfusion buffer.  
Each heart was administered three doses of ISO (1, 2 and 10 nM), and maintained at a constant 
coronary perfusion pressure of 70 mmHg by increasing coronary flow as vasodilation occurred.  
Steady-state responses to ISO were assessed after approximately two minutes infusion of each 
dose.  
D. Data and Statistical Analysis 
 Data were analyzed with GraphPad Prism software and presented as means ± SE.  T-tests, 
one-way ANOVAs and two-way repeated measures ANOVAs were performed when appropriate.  
Post-hoc analysis using the Bonferroni’s method was performed when necessary.  Statistically 
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significant differences in the values were taken at p < 0.05.  
IV. Results 
A. Body and Tissue Weights 
Intact females weighed less than age-matched males, and absolute ventricular weight was 
also significantly lower in intact females as compared to males (Table 2, below; weights taken 
from multiple series of experiments). However, the ventricular weight/body weight ratio was no 
different between males and females. 
Table 2- Body and tissue weights in wild type mice 
 Body Wt. (g) Ventricular Wt. (mg) 
Ventricular Wt./Body 
Wt. (mg/g) 
Uterine Wt/Body 
Wt. (mg/g) n 
Males 28 ± 1 132 ± 2 4.8 ± 0.1 - 20 
Intact 
Females 20 ± 1* 103 ± 4* 5.2 ± 0.2 4.0 ± 0.5 17 
OvX 
Females 22 ± 1*,† 107 ± 4* 5.0 ± 0.2 0.4 ± 0.1† 14 
Data are means ± SE, analyzed using one-way ANOVA or t-test. *p<0.05 intact female vs. male, 
†p<0.05 OvX female vs. intact female 
Body weight was significantly increased in ovariectomized females relative to intact 
females, with no difference in ventricular weight or ventricular weight/body weight ratio.  
Uterine weight/body weight ratio was significantly reduced in OvX females, confirming ovarian 
hormone withdrawal. 
B. Baseline Hemodynamics 
 There were no differences in the baseline contractile parameters between males and intact 
females (Table 3; baseline values averaged from several series of experiments).  Coronary flow 
normalized to ventricular weight was significantly higher in intact females than in males. 
Table 3- Baseline hemodynamics in wild type mice 
 LVSP (mmHg) +dP/dt (mmHg/sec) 
-dP/dt 
(mmHg/sec) 
Coronary Flow 
(mL/min/g) n 
Male 100 ± 2 4014 ± 104 -2304 ± 57 19 ± 1 30 
Intact Female 103 ± 2 4150 ± 163 -2426 ± 88 23 ± 1* 27 
OvX Female 90 ± 3*,† 3334 ± 138*,† -2039 ± 88† 22 ± 1 14 
Data are means ± SE, analyzed using one-way ANOVA.  LVSP- left ventricular systolic pressure. 
*p<0.05 intact, OvX female vs. male, †p<0.05 OvX female vs. intact female 
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Ovariectomized females had a significantly lower baseline LVSP, +dP/dt and -dP/dt than 
intact females.  LVSP and +dP/dt in OvX females were also significantly lower than in males.  
However, ovariectomy did not alter coronary flow in females.    
C. β-Adrenergic Contractile Responses 
 The β-adrenergic contractile response to ISO (1, 2 and 10 nM) in hearts from males, 
intact females and ovariectomized females is presented in Figure 3A-D.  While LVSP increased 
upon ISO stimulation, slight decreases were seen in LV diastolic pressure.   
 
Figure 3- Hemodynamic responses to ISO. Presented as % change from pre-ISO baseline in 
male (n=10), intact female (n=7) and ovariectomized female (n=8) mouse hearts (A- LVSP, B- 
+dP/dt, C- -dP/dt and D- coronary flow). Data are means ± SE, analyzed using two-way 
ANOVA with repeated measures.  *p<0.05 between groups (male, intact female, OvX female) 
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 Males showed a greater contractile response to ISO than did intact and ovariectomized 
females (in terms of LVSP, +dP/dt and –dP/dt).  For example, at 1 nM ISO the percent increases 
in LVSP for males and intact females were 64 ± 7 and 39 ± 5%; for +dP/dt, 101 ± 15 and 54 ± 
8%, and for –dP/dt, 122 ± 14 and 67 ± 10%, respectively.  At 1 nM ISO the percent increase in 
LVSP for ovariectomized females was 45 ± 5%, for +dP/dt, 67 ± 7%, and for –dP/dt, 80 ± 12%.  
 Along with an increase in contractility, administration of ISO resulted in coronary 
dilation.  Percent changes were calculated using raw coronary flow data, not normalized to 
ventricular weight, which was not different between the groups (in mL/min, males- 2.4 ± 0.1, 
intact females- 2.1 ± 0.2; OvX females- 2.3 ± 0.2).  There were no differences between the 
groups in their dilatory response to ISO (p=0.0620).  Percent increases from baseline coronary 
flow of 39 ± 5% in males, 25 ± 3% in intact females and 23 ± 4% in ovariectomized females 
were observed at 2 nM ISO.   
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Chapter 3: Modulation of the β-Adrenergic Contractile Response by the A1 Adenosine 
Receptor in Males, Intact Females and Ovariectomized Females- Methods and Results 
I. Rationale 
 Females displayed a reduced contractile response to β-adrenergic receptor stimulation as 
compared to males in the isolated heart.  As mentioned in the Background, the A1 adenosine 
receptor (A1AR) is known to negatively modulate the βR contractile response.  To test the theory 
that sex differences exist in the A1AR anti-adrenergic effect, contributing sex differences in the 
βR response, two series of experiments were performed.  First, activation of the A1AR using 
selective agonist CCPA was performed prior to ISO administration to blunt the normal β-
adrenergic contractile response.  While ovariectomy was not found to alter the βR contractile 
response, the A1AR anti-adrenergic effect was tested in OvX mice as well.  Secondly, the role of 
endogenous adenosine in modulating the βR response in both males and females was 
investigated using A1ARKO mice.  Due to limitations in number of available A1ARKO mice, 
and since there were no differences in the normal βR response between intact and OvX females, 
these studies were not performed in ovariectomized A1ARKO mice. 
 Interesting results in the aforementioned studies led to the development of an additional 
series of experiments. A1AR, A2aAR and A2bAR function in the isolated heart was investigated 
using the non-selective AR agonist 5’-(N-Ethylcarboxamideo)adenosine.  This experiment 
enabled an analysis of A1AR-mediated reductions in heart rate, as well as A2aAR and A2bAR-
mediated coronary vasodilation in a single heart.   
II. Materials 
 KHB and ISO were purchased and prepared as described in Chapter 2.  5’-(N-
Ethylcarboxamideo)adenosine (NECA) and 2-chloro-N6-cyclopentyl-adenosine (CCPA) 
(Sigma-Aldrich Inc, St Louis, MO) were prepared as 10 mM stocks in dimethyl sulfoxide 
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(DMSO) and diluted as necessary.  DMSO concentration in the perfusate remained <0.1%.     
III. Methods 
A. Animal Model 
 Wild type male, intact female and ovariectomized female mice were obtained and 
handled as described in Chapter 2.  Global constitutive A1AR homozygous knockout (A1ARKO) 
male and female mice were obtained from A1AR heterozygous knockout breeders (C57BL/6 
background) provided by Jürgen Schnermann (NIDDK), and genotype was confirmed by tail-
snip PCR (performed by Transnetyx, Memphis TN). 
B.  Isolated Heart Preparation  
 Performed as described in Chapter 2, with the exception that pacing wires were not 
inserted into ventricular tissue in the NECA dose response study. 
C.  Protocol: Modulation of βR Contractile Response by A1AR Activation  
Hearts from wild type males, intact females and ovariectomized females were allowed to 
equilibrate for approximately 20 minutes prior to initiation of the experimental protocols.  Both 
CCPA and ISO were added directly to the perfusion buffer. Hearts were infused with 200 nM 
CCPA (an A1AR agonist) for five minutes prior to and during ISO exposure.  The ISO dose 
response protocol was performed as described in Chapter 2. 
D. Protocol: Modulation of βR Contractile Response by A1AR Deletion 
 The ISO dose response protocol was performed as described in Chapter 2, using male and 
female A1ARKOs. 
E. Protocol: Study of Adenosine Receptor Function using NECA 
Hearts were allowed to equilibrate for approximately 20 minutes prior to initiation of the 
experimental protocol.  NECA dose response studies were performed at constant coronary flow 
in unpaced hearts, to monitor changes in coronary perfusion pressure as well as heart rate.  
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Hearts were infused with the following doses of NECA (in nM: 0.5, 1, 5, 10, 50, 100, 500, and 
1000), and steady-state responses to each dose were assessed after two minutes of infusion. 
F. Data and Statistical Analysis 
 Performed as described in Chapter 2, using a two-way ANOVA with repeated measures. 
III. Results 
A. Modulation of βR Contractile Response by A1AR Activation 
Treatment with 200 nM CCPA significantly increased LVSP, +dP/dt and –dP/dt in both 
males and intact females, with no effect on these parameters in ovariectomized females, shown 
in Table 4.  Coronary flow was increased following CCPA treatment in all three groups. 
Table 4- Hemodynamic responses to 200 nM CCPA in wild type mice 
 LVSP (mmHg) +dP/dt (mmHg/sec) -dP/dt (mmHg/sec) Coronary Flow (mL/min/g) 
 Baseline CCPA Baseline CCPA Baseline CCPA Baseline CCPA 
Male 
(n=8) 97 ± 2 106 ± 3* 3959 ± 182 4422 ± 228* -2291 ± 115 -2563 ± 131* 18 ± 1 21 ± 2* 
Intact 
Female 
(n=6) 
95 ± 7 99 ± 7* 3849 ± 480 4101 ± 521* -2318 ± 289 -2509 ± 334* 23 ± 3 25 ± 3* 
OvX 
Female 
(n=6) 
91 ± 2 94 ± 2 3421 ± 197 3546 ± 197 -2114 ± 106 -2212 ± 114 20 ± 2 22 ± 2* 
Data are means ± SE, analyzed using a two-way ANOVA with repeated measures. LVSP- left ventricular 
systolic pressure. *p<0.05 CCPA vs. baseline 
Contractile responses to ISO following CCPA pre-treatment (shown in Figure 4) were 
much reduced as compared to control ISO responses seen in Figure 3.  Intact females 
demonstrated an enhanced A1AR anti-adrenergic effect as compared to males.  CCPA 
pretreatment reduced the mean contractile response to 2 nM ISO by approximately 60% in males 
and 90% in females (LVSP, +dP/dt and –dP/dt).  With CCPA pre-treatment, intact female 
contractile responses to ISO were significantly lower than male responses at all three doses in the 
three contractile parameters (excluding +dP/dt at 1 nM).  Coronary flow responses were only 
reduced in intact females as compared to males at 10 nM ISO. 
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 The potentiation of the A1AR anti-adrenergic effect in females was lost following 
ovariectomy (40% reduction at 2 nM ISO in CCPA pre-treated as compared to control ISO 
treatment).  Following CCPA pre-treatment, contractile responses to ISO in hearts from OvX 
mice were significantly greater than in hearts from intact females at both 2 and 10 nM ISO 
(LVSP, +dP/dt and –dP/dt).  Coronary flow responses were higher in OvX females as compared 
to intact females at 2 and 10 nM ISO, with no differences at 1 nM ISO. 
Figure 4- Hemodynamic responses to ISO with 200 nM CCPA pre-treatment. Presented as % 
change from pre-ISO baseline in male (n=8), intact female (n=6) and ovariectomized female 
(n=6) mouse hearts (A- LVSP, B- +dP/dt, C- -dP/dt, D- coronary flow).  Data are means ± SE, 
analyzed using two-way ANOVA with repeated measures. *p<0.05 intact female vs. male for 
corresponding dose of ISO; †p<0.05 intact female vs. ovx female for corresponding dose of ISO. 
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B. Modulation of βR Contractile Response by A1AR Deletion 
Body weight was lower in age-matched A1ARKO as compared to wild type (WT) males 
(24 ± 1 vs. 28 ± 1 g), while it was higher in A1ARKO as compared to WT females (23 ± 1 vs. 20 
± 1 g).  Additionally, while there were no differences in ventricular weight/body weight ratio in 
A1ARKO versus WT males (4.8 ± 0.2 vs. 4.5 ± 0.1 mg/g), the ratio was significantly higher in 
A1ARKO compared to WT females (5.6 ± 0.7 vs. 4.6 ± 0.1 mg/g). 
As illustrated in Figure 5, deletion of the A1AR resulted in potentiation of the β-
adrenergic contractile response in both males and females (as compared to Figure 3). 
Figure 5- Hemodynamic responses to ISO in A1ARKO hearts.  Presented % change from pre-
ISO baseline in male (n=3) and intact female (n=6) mouse hearts (A- LVSP, B- +dP/dt, C- -
dP/dt, D- coronary flow).  Data are means ± SE, analyzed using a two-way ANOVA with 
repeated measures.  *p<0.05 A1ARKO female vs. A1ARKO male 
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In both male and female A1ARKOs, the LVSP response at 1 nM ISO was enhanced by 
92% versus their WT counterparts.  Sex differences were not present in the contractile response 
to ISO at any dose, in any parameter (LVSP, +dP/dt, -dP/dt).  However, sample size may have 
limited detection of significant sex differences, with p=0.0663 for LVSP and p=0.0879 for –
dP/dt, and adding more animals (particularly males) may have resulted in detection of a sex 
effect in the A1ARKO response to ISO.  There was a sex effect on the vascular response to ISO 
in A1ARKOs, with male dilation being greater than females.  For example, at 1 nM ISO, the 
percent increase in coronary flow in males was 39 ± 3%, and in females was 26 ± 3%. 
C. Chronotropic and Vascular Actions of AR  
 There were no differences among males, intact females and ovariectomized females in 
terms of baseline heart rate (in bpm: 339 ± 12, 333 ± 4 and 340 ± 16 respectively) or coronary 
flow (in ml/min/g: 14 ± 1, 15 ± 1 and 15 ± 1).  NECA administration resulted in potent decreases 
in both heart rate (via the A1AR) and coronary perfusion pressure (via the A2aAR and A2bAR). 
Figure 6- Hemodynamic responses to NECA.  Presented as % change from pre-NECA baseline 
in male (n=3 at 0.5 and 1 nM, n=7 for 5 nM and higher), intact female (n=3 at 0.5 and 1 nM, n=6 
for 5 nM and higher) and ovariectomized female (n=4) mouse hearts (A- heart rate and B- 
coronary perfusion pressure).  Data are means ± SE, analyzed using a two-way ANOVA.   
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 As shown in Figure 6, there were no sex differences in the heart rate or coronary 
perfusion pressure responses to NECA.  Additionally, ovarian hormone withdrawal in females 
did not change heart rate or dilatory responses to NECA. 
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Chapter 4: Modulation of the G Protein Signaling Pathway in the Isolated Heart- Methods 
and Results 
I. Rationale 
 The contractile responses elicited by β-adrenergic receptor activation occur in part due to 
manipulation of downstream signaling pathways.  The secondary hypothesis of this study was 
that females would show altered expression or function of components of the βR system.  
Pharmacological tools which manipulate components of the βR signaling pathway may be used 
to alter their activity, and can address the possibility that males and females differ in expression 
and/or function of proteins downstream of the β-adrenergic receptors. 
 Both the β1 and β2-adrenergic receptors couple to Gsα protein, and stimulate adenylyl 
cyclase (AC) upon ligand binding.  β2-adrenergic receptors can also couple to Giα protein, and 
inhibit adenylyl cyclase upon their activation.  When administered to the isolated heart, forskolin 
elicits increases in contractility by directly activating adenylyl cyclase.  Activation of the βR 
signaling pathway results in stimulation of phosphodiesterases which hydrolyze cAMP, and the 
nonselective phosphodiesterase inhibitor 3-Isobutyl-1-methylxanthine increases contractility in 
the isolated heart by preventing degradation of cAMP.  Functional responses to βR stimulation 
are due in large part to actions of the second messenger cAMP, and a non-hydrolyzable analog of 
cAMP (CPT-cAMP) was administered to the isolated heart to test if there are sex differences 
downstream of cAMP which contributes to sex differences in the βR response.  
II. Materials 
 KHB was purchased and prepared as described in Chapter 2. Forskolin (FSK), 3-
Isobutyl-1-methylxanthine (IBMX), and 8-(4-Chlorophenylthio)adenosine 3′,5′-cyclic 
monophosphate (CPT-cAMP) (Sigma-Aldrich Inc, St Louis, MO) were prepared as 10 mM 
stocks in DMSO and diluted as necessary.  Final DMSO concentration in the perfusate was 
<0.1%. 
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III. Methods 
A. Animal Model 
 Male and female mice were purchased and handled as described in Chapter 2. 
B.  Isolated Heart Preparation  
 Performed as described in Chapter 2.  Baseline hemodynamic values were similar to 
those reported in previous chapters.  
C. Forskolin, IBMX and CPT-cAMP Dose Response Protocols 
Hearts were allowed to equilibrate for approximately 20 minutes prior to initiation of the 
experimental protocols.  Hearts were administered forskolin (in nM 100, 300, 500, 750, 1000, 
5000); IBMX (in μM 0.5, 1, 10, 25, 50, 100); or CPT-cAMP (in μM 5, 10, 25, 50).  Steady state 
responses in cardiac function and coronary flow were assessed after five minutes infusion of 
each dose. 
D. Data and Statistical Analysis 
 Performed as described in Chapter 2, using two-way ANOVAs with repeated measures.  
IV. Results 
A. Adenylyl Cyclase Activation in Males and Females 
 As shown in Figure 7, forskolin administration resulted in increases in both contractility 
and coronary flow.  There were no sex differences in the contractile response to forskolin in 
terms of LVSP, +dP/dt or -dP/d.  At 5 μM, the percent increase from baseline in LVSP was 77 ± 
5 in males and 62 ± 5 in females; the percent increase from baseline in +dP/dt was 145 ± 5 in 
males and 116 ± 10 in females, and the percent increase from baseline in -dP/dt was 129 ± 9 in 
males and 105 ± 9 in females. 
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Figure 7- Hemodynamic responses to forskolin.  Presented as % change from pre-forskolin 
baseline in male (n=8) and female (n=8) mouse hearts (A- LVSP, B- +dP/dt, C- -dP/dt, and D- 
coronary flow).  Data are means ± SE, analyzed using two-way ANOVA with repeated 
measures. *p<0.05 male vs. female  
 Male hearts showed greater dilatory responses to FSK administration than did female 
hearts.  For example, at 300 nM FSK, the percent increase from baseline in coronary flow in 
males was 17 ± 2, and was 11 ± 2 in females.   
B.  Phosphodiesterase Inhibition in Males and Females 
 As shown in Figure 8, PDE inhibition with IBMX resulted in increases in both 
contractility and coronary flow.  There were no sex differences in the contractile responses to 
IBMX.   
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Figure 8- Hemodynamic responses to IBMX.  Presented as % change from pre-IBMX baseline 
in male (n=3) and female (n=3) mouse hearts (A- LVSP, B- +dP/dt, C- -dP/dt, and D- coronary 
flow).  Data are means ± SE, analyzed using a two-way ANOVA with repeated measures. 
 
 Males showed a tendency toward greater coronary flow response to PDE inhibition at 
higher doses of IBMX (p=0.0883).  For example, at 25 μM IBMX, with males showing an 
increase from baseline of 19 ± 2%, and females showing an increase from baseline of 11 ± 2%.  
However, limited animal numbers prevented detection of statistical significance in this parameter.  
C.  Activation of cAMP-dependent Signaling in Males and Females 
 Activation of the cAMP signaling cascade using non-hydrolyzable analogue CPT-cAMP 
resulted in increases in contractility and coronary flow.  As shown in Figure 9, there were no 
differences in the contractile responses to CPT-cAMP, in terms of LVSP, +dP/dt and –dP/dt.   
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Figure 9- Hemodynamic response to CPT-cAMP.  Presented as % change from pre-CPT-cAMP 
baseline in male (n=3) and female (n=3) mouse hearts (A- LVSP, B- +dP/dt, C- -dP/dt, and D- 
coronary flow). Data are means ± SE, analyzed a two-way ANOVA with repeated measures. 
 While males showed a tendency toward greater dilatory responses at increasing doses of 
CPT-cAMP than females, there were no statistically significant differences in flow responses 
between sexes.  However, limited animal numbers likely prevented detection of statistical 
significance in this parameter. 
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Chapter 5: β-Adrenergic and Adenosine Receptor Gene Expression in Males, Intact 
Females and Ovariectomized Females- Methods and Results 
I.  Rationale 
 The classical function of sex steroid hormones is modulation of gene transcription via 
binding to their nuclear receptors.  Sex differences in the expression of many genes have been 
documented, and a role for sex steroid hormones in modulating gene expression has been shown 
using gonadectomy models. 
 Since females exhibited a reduced β-adrenergic receptor contractile response as compared 
to males, it was predicted that females could show reduced β1R expression as compared to males.  
Additionally, intact females showed a dramatically enhanced A1AR anti-adrenergic effect as 
compared to both males and ovariectomized females.  It was therefore predicted that intact 
females may show an enhanced A1AR expression and/or reduced A2aAR expression (which 
antagonizes the A1AR). 
 To investigate receptor expression, Real Time RT-PCR was performed in both 
ventricular tissue and ventricular myocytes.  This is a powerful technique used to assess 
expression of a gene, quantified relative to an internal control gene.  While it would be ideal to 
assess expression of β-adrenergic receptor and adenosine receptor protein using western blotting, 
severe limitations in the quality and specificity of antibodies for western blotting prevented this 
method of analysis from being performed.  Several commercially available β1R and A1AR 
antibodies were tested under different SDS-PAGE and western conditions.  Multiple bands were 
detected for the β1R, due to post-translational processing of the receptor (Rybin et al. 2000), 
which complicates quantification.  A1AR antibodies were tested using A1ARKO tissue as a 
negative control, and in all cases a band was detected at the predicted molecular weight for the 
A1AR in both WT and KO tissue (though gene ablation was confirmed using PCR). 
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II. Materials   
A. Ventricular Myocyte Isolation  
 NaCl, KCl, KH2PO4, MgSO4, NaHCO3, HEPES, glucose, taurine, 2,3-butanedione 
monoxime, sodium pyruvate, and Protease Type XIV were purchased Sigma-Aldrich, Inc (St 
Louis, MO).  Collagenase Type B and Type D were purchased from Roche Diagnostics 
(Mannheim, Germany). 
B. RNA Isolation and PCR 
 Trizol reagent was purchased from Invitrogen (Carlsbad, CA).  DNase I and the RNEasy 
Mini Kit were purchased from Qiagen (Valencia, CA).  All reagents necessary for reverse 
transcription and real-time PCR were purchased from Applied Biosystems (Carlsbad, CA). 
III. Methods 
A. Ventricular Myocyte Isolation 
Hearts were excised from anesthetized (Avertin, 400 mg/kg) and heparinized (500 units) 
mice, placed in ice-cold saline and mounted on a perfusion apparatus.  Hearts were perfused for 
3-4 minutes at a baseline CPP of 60 mmHg with isolation buffer, in mM: NaCl 120, KCl 4.7, 
KH2PO4 1.2, MgSO4 1.2, NaHCO3 5, HEPES 10, glucose 11, taurine 30, 2,3-butanedione 
monoxime 10, sodium pyruvate 5, pH adjusted to 7.2 using NaOH.  Isolation buffer was filtered 
during the perfusion using a 0.22 μm in-line filter.  Digestive enzymes were then added to the 
isolation buffer, for a final concentration of 0.5 mg/ml Collagenase B, 0.5 mg/ml Collagenase D, 
0.02 mg/ml Protease Type XIV and 50 μM CaCl2.  Flow was maintained constant unless 
excessive vasoconstriction occurred at the early stage of digestive enzyme perfusion, at which 
point flow was reduced, and then returned to baseline level as subsequent vasodilation occurred 
(indicating digestion).  Perfusion was performed for 10-14 minutes, until CPP was reduced to 
<30 mmHg, indicating adequate digestion.  Hearts were removed from the cannula, aorta and 
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connective tissue was excised, and the remaining ventricular tissue was minced with 
microscissors.  The tissue was suspended in ~ 5 mL isolation buffer with 0.5% BSA and 50 μM 
CaCl2, and gently dissociated with large and small tip plastic pipettes.  The suspension was 
filtered through cheesecloth into a 15 mL Eppendorf tube, and then allowed to settle by gravity.  
The pellet (containing mostly rod-shaped myocytes) was resuspended in isolation buffer with 
0.5% BSA and 100 μM CaCl2.  Calcium concentration was slowly restored to 1.2 mM, and then 
the cells were pre-plated in a tissue culture dish for 2 hours at 37°C.  Following pre-plating, cells 
were collected for RNA isolation. 
B. RNA Isolation and Real Time Quantitative PCR 
For gene expression analysis in ventricular tissue, hearts were rapidly excised and placed 
in ice-cold saline, extraneous tissue (including atria) was removed, and the ventricular tissue was 
flash frozen in liquid nitrogen and stored at -80°C until RNA isolation. For gene expression 
analysis in ventricular myocytes, pre-plated cells were settled by gravity and the pellet was flash-
frozen in liquid nitrogen and stored at -80°C until RNA isolation. 
Total RNA was isolated using 1 mL of Trizol reagent. RNA was digested with DNase I 
and purified using the RNeasy Mini Kit, according to the manufacturer’s instructions.  RNA 
quantity and quality was validated by spectrophotometry (i.e. A260/A280 ratio of ~2.2) and 
agarose gel electrophoresis (presence of 18S and 28S RNA).  Reverse transcription was 
performed on 1 µg of total RNA using the High Capacity cDNA reverse transcription kit.  Gene 
expression was assayed with TaqMan Universal PCR Master Mix and FAM-labeled TaqMan 
inventoried gene expression assays according to manufacturer’s instructions.  Real time PCR 
was conducted using the StepOnePlus Real-Time PCR System.  Data was analyzed by the 
comparative 2-ΔΔCt method using GAPDH as an endogenous control (GAPDH showed no 
difference in Ct values between males, intact females and ovariectomized females, data not 
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shown).  Expression of the gene of interest was calculated as fold difference relative to intact 
females. 
C. Data and Statistical Analysis 
 Data were analyzed with GraphPad Prism software and presented as means ± SE.  One-
way ANOVAs were performed, with Post-hoc analysis using the Bonferroni’s method used 
when necessary.  Statistically significant differences in the values were taken at p < 0.05.  
IV. Results 
A. Gene Expression in Ventricular Tissue 
 There were no sex differences in the expression of β1R or β2R in ventricular tissue, 
shown in Figure 10A.  Ovariectomy resulted in a modest decrease in β1R receptor gene 
expression (0.72 ± 0.05 relative to intact female), with no changes in β2R gene expression. 
Figure 10- Expression of β-adrenergic receptors (A) and adenosine receptors (B) in ventricular 
tissue. n=5 for male, intact female and ovariectomized female mice.  Data are expressed in fold 
difference relative to intact female.  Data are means ± SE, analyzed using one-way ANOVA.  
*p<0.05 male vs. intact female, †p<0.05 intact female vs. ovariectomized female. 
 
 Intact females expressed a slightly, but significantly, higher level of the A1AR gene in 
ventricular tissue than both males and ovariectomized females (fold difference relative to intact 
females: males 0.73 ± 0.07, OvX females 0.71 ± 0.02).  There were no differences in the 
expression of the other adenosine receptor subtypes. 
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B. Gene Expression in Ventricular Myocytes 
 There were no sex differences in the expression of either βR subtype in ventricular 
myocytes.  Additionally, ovariectomy did not alter the expression of either βR subtype (shown in 
Figure 11A). 
Figure 11- Expression of β-adrenergic receptors (A) and adenosine receptors (B) in ventricular 
myocytes.  Data are presented for wild type male (n=4), intact female (n=4) and ovariectomized 
female (n=3) mice.  Data are expressed in fold difference relative to intact female.  Data are 
means ± SE, analyzed using one-way ANOVA  *p<0.05 male vs. intact female, †p<0.05 intact 
female vs. ovariectomized female. 
 
 The enhanced A1AR expression in female ventricular tissue was not seen in ventricular 
myocytes (Figure 11B).  However, A3AR expression was greater in intact female myocyte 
samples as compared to both males (0.52 ± 0.07 fold difference relative to intact females) and 
ovariectomized females (0.61 ± 0.02 fold difference relative to intact females). 
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Chapter 6: Expression of Components of the G Protein Signaling Pathway in Males and 
Females- Methods and Results 
I. Rationale 
 βR contractile responses were reduced in females as compared to males, and  β1R and 
β2R gene expression did not differ between males and females.  While the possibility cannot be 
excluded that receptor protein expression differs between males and females, the next point of 
investigation into a potential mechanism for the reduced response to ISO in females was at the 
level of expression of components of the βR signaling pathway. 
 Relevant subtypes of some of the targets assessed on the functional level in Chapter 4 
were addressed at the level of protein expression.  Namely, the predominant cardiac isoforms of 
adenylyl cyclase are types V and VI (Ishikawaet al. 1997).  PDE4D is expressed in cardiac 
myocytes and has been demonstrated to modulate βR subtype-specific signaling (De Arcangelis 
et al. 2010).  Additionally, the expression of Gsα and Gi-2α (a form having been shown to couple 
to the β2R) (Xaio et al. 1999) proteins, as well as protein phosphatase 1 and protein phosphatase 
2A, were considered.  If the expression of one or multiple components of the βR signaling 
pathway were altered in females (as predicted in Hypothesis 2), it could help explain the reduced 
βR contractile response in female hearts. 
II. Materials 
 Isolation buffer and digestive enzymes were purchased and prepared as described in 
Chapter 6.  SIGMAFAST Protease Inhibitor Cocktail was purchased from Sigma Aldrich, Inc (St 
Louis, MO).  Phosphatase Inhibitor Cocktail was purchased from Nacalai Tesque (San Diego, 
CA).  Materials for western blotting were purchased from BioRad (Hercules, CA).  Anti-
adenylyl cyclase V/VI, anti-Gsα protein, anti-Gi-2α protein and anti-phosphodiesterase 4D 
primary antibodies were purchased from Santa Cruz (Santa Cruz, CA).  Anti-GAPDH 
conjugated to horseradish peroxidase (HRP), anti-PP2A C subunit primary antibody, and goat 
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anti-rabbit secondary antibody were purchased from Cell Signaling (Danvers, MA).  Anti-PP1 
antibody was purchased from Upstate/Millipore (Billerica, MA).  Goat anti-mouse secondary 
antibody was purchased from Jackson Immunoresearch (West Grove, PA).  Enhanced 
chemiluminesence (ECL) was purchased from Pierce (Rockford, IL).   
III. Methods  
A. Animal Model and Ventricular Myocyte Isolation 
 Performed as described in Chapter 5.  
B.  Generation of Ventricular Myocyte Lysate 
 Following pre-plating, the myocyte suspension was spun at 1000 rpm for 15 seconds.  
The isolation buffer was aspirated, and the cells were washed once with ice-cold buffer and spun 
at 1000 rpm for 15 seconds.  Cells were resuspended in lysis buffer: 50 mM Tris pH 7.4, 150 
mM NaCl, 5 mM EDTA, 1% Triton-X 100, 1X SIGMAFAST protease inhibitor cocktail and 1X 
Phosphatase inhibitor cocktail.  Sonication was performed (3 quick bursts), and the lysate was 
kept on ice for 20 minutes and vortexed every five minutes.  The lysate was spun at 10,000g for 
5 minutes, and the supernatant from this spin was stored at -80°C until study.  Protein 
concentration was assayed using the Bradford method. 
C. SDS-PAGE and Western Blotting 
 For all proteins of interest, 25 μg of myocyte lysate was loaded on a 10% polyacrylamide 
gel, with lamelli buffer (final concentration of 1.25X SDS), and 10% β-mercaptoethanol.  
Following SDS-PAGE, proteins were transferred to 0.2 μm nitrocellulose membranes.  Protein 
loading was assessed following transfer using Ponceau Stain.  Membranes were blocked for 1 
hour in 5% instant nonfat dry milk (Carnation) in TBS with 0.05% Tween-20 (TBST), then 
washed three times with TBST.  All antibodies were incubated overnight at 4°C in TBST with 
1% milk with gentle rocking.  The following primary antibody dilutions were used: 
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Table 5- Primary antibody dilutions for western blotting 
Protein Target Dilution 
Adenylyl cyclase V/VI (rabbit polyclonal) 1:100 
Gsα protein (rabbit polyclonal) 1:1000 
Gi-2α protein (rabbit polyclonal) 1:1000 
PDE4D (rabbit polyclonal) 1:500 
PP1 (mouse monoclonal) 1:500 
PP2A (rabbit polyclonal) 1:500 
 
 Following overnight incubation with primary antibody, membranes were washed three 
times with TBST.  Membranes were then incubated for one hour at room temperature (gentle 
rocking) with secondary antibody (goat anti-rabbit or goat anti-mouse), at a dilution of 1:5000 
(excluding PP1, PP2A which required a secondary dilution of 1:2500), or loading control 
GAPDH conjugated to HRP (1:5000), all in TBST with 1% milk.  Membranes were then washed 
three times with TBST, one time with TBS, and exposed to ECL for autoradiography.  Due to the 
molecular weight of PP1 and PP2A, these blots were stripped with glycine stripping buffer and 
reprobed for GAPDH as described.  
D.  Data and Statistical Analysis 
 Quantification of band density was performed using UN-SCAN IT Gel Version 6.1.  Data 
were analyzed with GraphPad Prism software and presented as means ± SE.  Data were analyzed 
using an unpaired t-test.  Statistically significant differences in the values were taken at p < 0.05.  
IV. Results 
 For each protein of interest, the original blot and quantification of expression relative to 
GAPDH (detected as a single band at the predicted molecular weight of 37 kD) is presented.  
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Figure 12- Gsα protein expression in myocytes- quantification and original blot. n=5 myocyte 
lysates for male and female.  Expression is quantified relative to loading control GAPDH, with 
data expressed as means ± SE.   
 A single band for Gsα protein was detected near the predicted molecular weight of 45 kD.  
There were no differences in the expression of Gsα protein between males and females in 
ventricular myocytes. 
 
Figure 13- Gi-2α protein expression in myocytes- quantification and original blot.   n=5 myocyte 
lysates for male and female Expression is quantified relative to loading control GAPDH, with 
data expressed as means ± SE.   
 A single band for Gi-2α protein was detected near the predicted molecular weight of 41 
kD.  There were no differences in the expression of Gi-2α between males and females in 
ventricular myocytes. 
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Figure 14- Adenylyl cyclase V/VI expression in myocytes- quantification and original blot.   
n=5 myocyte lysates for male and female.  Expression is quantified relative to loading control 
GAPDH, with data expressed as means ± SE.   *p<0.05 female vs. male  
 Adenylyl cyclase V/VI was detected as a single band near the predicted molecular weight 
of 132 kD.  As shown in Figure 14, females express significantly higher levels of adenylyl 
cyclase V/VI than males in ventricular myocytes (3.76 ± 0.74 vs. 1.52 ± 0.09). 
 
Figure 15- Phosphodiesterase 4D expression in myocytes- quantification and original blot.  n=5 
myocyte lysates for male and female.  Expression is quantified relative to loading control 
GAPDH, with data expressed as means ± SE.    
 PDE4D was detected as a single band at a molecular weight of ~75 kD (predicted 
molecular weight for various isoforms 65-119 kD).  There were no differences in the expression 
of PDE4D between males and females. 
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Figure 16- Protein phosphatase 1 expression in myocytes- quantification and original blot.  n=5 
myocyte lysates for male and female.  Expression is quantified relative to loading control 
GAPDH, with data expressed as means ± SE.   
 Protein phosphatase 1 was detected as a single band at the predicted molecular weight of 
38 kD.  There were no differences in the expression of PP1 in ventricular myocytes between 
males and females. 
 
Figure 17- Protein phosphatase 2A expression in myocytes- quantification and original blot.  
n=5 myocyte lysates for male and female.  Expression is quantified relative to loading control 
GAPDH, with data expressed as means ± SE.    
 A single band at the predicted molecular weight of protein phosphatase 2A was detected 
(two forms exist at 36, 38 kD).  There were no sex differences in the expression of PP2A in 
ventricular myocytes. 
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Chapter 7: cAMP Accumulation following βR Stimulation in Male and Female Myocytes- 
Methods and Results 
I. Rationale 
 Stimulation of the β-adrenergic receptors with ISO leads to increases in contractility via a 
cAMP-dependent mechanism.  It was predicted that sex differences in β-adrenergic receptor 
responses to ISO occur at the level of the ventricular myocyte, the major contractile cell of the 
heart.  If the sex differences seen in the βR response are cAMP-dependent, determining the 
extent cAMP accumulation in ventricular myocytes using an enzyme-linked immunosorbent 
assay (ELISA) would detect these differences. 
 ISO stimulations that are performed for measurement of cAMP are often performed in 
the presence of a phosphodiesterase inhibitor.  As mentioned in the Background, PDE4 is 
activated upon βR stimulation to prevent excessive generation of cAMP (and consequently 
excessive contractile responses). Studies were therefore performed with and without the PDE4 
inhibitor rolipram, in order to determine if PDE is more active in limiting cAMP generation in 
females than males.   
II. Materials 
 Isolation buffer, digestive enzymes, and ISO were purchased from companies described 
in previous chapters.  Rolipram was purchased from Tocris Bioscience (Minneapolis, MN).  The 
alkaline phosphatase cAMP Complete ELISA Kit was purchased from Enzo Life Sciences 
(Farmingdale, NY).   
III. Methods 
A. Animal Model and Ventricular Myocyte Isolation 
 Performed as described in Chapter 5. 
B. Drug treatment, Lysis and ELISA 
Following pre-plating, the myocyte suspension was split into three 15 mL Eppendorf 
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tubes, allowing for one vehicle-treated (phosphate buffered saline, PBS) myocyte population and 
two drug-treated myocyte populations from a single heart.  The tubes were spun at 1000 rpm for 
15 seconds to obtain a myocyte pellet.  Each pellet was resuspended in 3 mL isolation buffer 
with 0.5% BSA, 1.2 mM CaCl2 along with the appropriate treatment (vehicle or drug).  Cells 
were treated with vehicle or a single dose of ISO (in nM: 1, 10, 100, 1000) for 10 minutes at 
37°C.  For PDE inhibition studies, cells were treated for 10 minutes with 1 μM rolipram prior to 
as well as during ISO treatments.  Following treatments, the tubes were placed on ice to arrest 
the cells, and then spun at 1000 rpm for 15 seconds.  Treatment buffer was aspirated, and the 
cells were washed once with ice-cold buffer and spun at 1000 rpm for 15 seconds.  The pellet 
(myocytes) was resuspended in 350 μL 0.1 M HCl with 0.5% Triton-X 100, and left at room 
temperature for 10 minutes for lysis.  The lysate was spun at 800g for 10 minutes, and the 
supernatant was stored at -80°C until study.  ELISA was performed according to the 
manufacturer’s instructions.  The 96-well plate was read using Molecular Devices SpectraMax 
M2.    Protein concentrations for each lysate were assayed using the Bradford Method. 
C.  Data and Statistical Analysis 
 SoftMax Pro Version 5 Software provides a 4 parameter logistic curve fitting program for 
quantification of cAMP concentration.  cAMP concentration was normalized to protein 
concentration.  Data were analyzed with GraphPad Prism software and presented as means ± SE.  
Data were analyzed using two-way ANOVAs.  Post-hoc analysis using the Bonferroni method 
was performed when necessary.  Statistically significant differences in the values were taken at p 
< 0.05. 
IV. Results 
A.  ISO Dose Response Studies 
 There were no sex differences in basal (i.e. PBS-treated) cAMP concentrations (1.73 ± 
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0.19 pmol/mg protein in males, 2.17 ± 0.16 pmol/mg protein in females).  ISO significantly 
increase cAMP content as compared to vehicle. 
 
Figure 18- cAMP accumulation following ISO treatment in myocytes.  n≥4 per ISO dose.  Data 
are means ± SE, analyzed using a two-way ANOVA with Bonferroni post hoc analysis.  *p<0.05 
male vs. female; †p<0.05 ISO dose vs. vehicle  
 Females tended to show greater cAMP accumulation upon ISO treatment as compared to 
males (p=0.0026 male versus female).  For example, at the 10 nM dose of ISO female cAMP 
content in pmol/mg protein was 5.88 ± 0.44 versus 4.20 ± 0.33 in males. 
B. Effect of PDE Inhibition on cAMP Accumulation 
 Rolipram treatment (1 μM) did not alter cAMP concentration in male or female myocytes 
(males= 2.15 ± 0.22 pmol/mg protein, females= 2.28 ± 0.22 pmol/mg protein). 
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Figure 19- cAMP accumulation following ISO treatment with and without rolipram pre-
treatment in myocytes.  n≥3 per ISO dose.  Data are means ± SE, analyzed using a two-way 
ANOVA with Bonferroni’s post hoc analysis.  *p<0.05 rolipram male vs. rolipram female at 10 
nM ISO; †p<0.05 ISO dose vs. vehicle; ‡p<0.05 rolipram vs. control  
 Phosphodiesterase 4 inhibition with rolipram pre-treatment did not significantly alter the 
1 nM ISO response.  However, rolipram pre-treatment did significantly increase the cAMP 
accumulation at the 10 nM dose of ISO in both males and females.  At the 10 nM dose of ISO, 
rolipram pre-treated females showed a greater cAMP response than rolipram pre-treated males 
(in pmol/mg protein: 16.06 ± 2.00 vs. 9.86 ± 1.72 respectively). 
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Chapter 8- Signaling in Response to β-Adrenergic Receptor Stimulation in Male and 
Female Myocytes- Methods and Results 
I. Rationale 
 cAMP which is generated following βR stimulation activates protein kinase A, resulting 
in the phosphorylation of multiple proteins which modulate the contractile state of the myocyte.  
Two of these proteins which are phosphorylated by PKA following βR stimulation are troponin I 
(TnI) at residue serine 23/24 and phospholamban (PLB) at residue serine 16.  Both of these 
proteins are involved in the positive lusitropic response to β-adrenergic receptor stimulation (as 
described in the Background).  Western blotting enables an analysis of the phosphorylation states 
of these proteins before and after ISO treatment in both males and females. 
 Hypothesis 2 stated that females show an altered expression and/or function of proteins 
which would result in their reduced contractile response to ISO.  In this context, it was predicted 
that females would show reduced phosphorylation responses to ISO in either one or both of these 
proteins, which would contribute the reduced lusitropic response to βR stimulation in females.  
II. Materials 
 Myocyte isolation materials, ISO and western blotting supplies were purchased as 
described in previous chapters.  Anti-phospho-TnI (Ser 23/24) and TnI antibodies were 
purchased from Cell Signaling (Danvers, MA).  Anti-phospho-PLB (Ser 16) was purchased from 
Millipore (Billerica, MA), and anti-PLB was purchased from Pierce Antibodies/Thermo 
Scientific (Rockford, IL). 
III. Methods 
A. Animal Model and Ventricular Myocyte Isolation 
 Performed as described in Chapter 5. 
 
47 
 
B. Drug Treatment and Preparation of Myocyte Lysate 
 Following pre-plating, the myocyte suspension was split into three 15 mL Eppendorf 
tubes, allowing for vehicle (PBS) and two drug-treated myocyte populations from a single heart.  
The tubes were spun at 1000 rpm for 15 seconds to obtain a myocyte pellet.  Each pellet was 
resuspended in isolation buffer with 0.5% BSA, 1.2 mM CaCl2 along with the appropriate 
treatment (vehicle or drug).  Cells were treated with vehicle or a single dose of ISO (10 or 100 
nM) for 10 minutes at 37°C.  The treatment buffer was aspirated, and the cells were washed once 
with ice-cold buffer and spun again at 1000 rpm for 15 seconds.  Cells were resuspended in lysis 
buffer: 50 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton-X 100, 1X SIGMAFAST 
protease inhibitor cocktail and 1X Phosphatase inhibitor cocktail.  Sonication was performed (3 
quick bursts), and the lysate was kept on ice for 20 minutes and vortexed every five minutes.  
The lysate was spun at 10,000g for 5 minutes, and the supernatant from this spin was stored at -
80°C until study.  Protein concentration was assayed using the Bradford method. 
C. SDS PAGE and Western Blotting 
 For TnI blots, 30 μg of protein was loaded onto 10% polyacrylamide gels, and for PLB 
blots, 50 μg of protein was loaded onto 12% polyacrylamide gels.  SDS-PAGE, transfer to 
nitrocellulose, as well as membrane blocking and washing were performed as described in 
Chapter 6.  The following dilutions were used for phospho-antibodies: pTnI 1:1000 in TBST 
with 2.5% BSA, pPLB 1:300 in TBST with 5% BSA.   Goat anti-rabbit secondary antibody was 
used at 1:5000 for pTnI detection, and 1:2000 for pPLB detection in TBST with 1% milk.  
Membranes were stripped using glycine stripping buffer and reprobed for total TnI (1:5000 
primary, 1:10000 goat anti-rabbit secondary), and total PLB (1:10,000 primary, 1:20,000 goat 
anti-mouse secondary), all in TBST with 1% milk.   
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D. Data and Statistical Analysis 
Data were analyzed with GraphPad Prism software and presented as means ± SE.  Data 
were analyzed using two-way ANOVAs.  Post-hoc analysis using the Bonferroni method was 
performed when necessary 
IV. Results 
A.  Troponin I Phosphorylation in Males and Females 
 There were no differences in vehicle-treated pTnI levels between males and females.  
Both the original blot and quantified levels of pTnI relative to TnI are presented in Figure 20.   
 
Figure 20- Phosphorylation of troponin I following ISO treatment in myocytes.  Data are shown 
for males (n=6) and females (n=5). Both the original blot and quantification (pTnI/TnI) are 
presented. Data were analyzed using a two-way ANOVA.  †p<0.05 ISO dose vs. baseline within 
group 
 Both pTnI and TnI were detected as a single band near the predicted molecular weight of 
28 kD.  Note that ISO treatment resulted in large increases in troponin I phosphorylation as 
compared to vehicle treatment.  Interestingly, there were no sex differences in the extent of TnI 
phosphorylation following ISO treatment.  For example, at 10 nM the ratio of pTnI to TnI in was 
0.52 ± 0.065 in male myocytes and was 0.56 ± 0.053 in female myocytes. 
B. Phospholamban Phosphorylation in Males and Females 
 There were no differences in vehicle-treated pPLB levels between males and females.  
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Both the original blot and quantified levels of pPLB/PLB are presented in Figure 21. 
Figure 30- Phosphorylation of phospholamban following ISO treatment in male (n=6) and 
female (n=5) myocytes. Both the original blot and quantification (pPLB/PLB) are presented. 
Data were analyzed using a two-way ANOVA.  *p<0.05 male vs. female at corresponding ISO 
dose  †p<0.05 ISO dose vs. baseline within group 
 Both pPLB and PLB were detected as a single band at the predicted molecular weight for 
the monomeric form of the protein, ~5 kD.  Note that ISO treatment resulted in increased 
phospholamban phosphorylation as compared to vehicle only in the female samples.  
Additionally, females showed a statistically greater PLB phosphorylation at the 100 nM dose of 
ISO (pPLB/PLB ratio of 1.77 ± 0.20 in females vs. 1.00 ± 0.11 in males).  
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Chapter 9: Discussion 
I.  Summary of Results 
 The previous chapters described the results of an investigation into sex differences in the 
β-adrenergic contractile response.  A summary of these findings is listed below: 
1. Females displayed a reduced contractile response to βR agonist isoproterenol as compared 
to males in the isolated heart.  Ovariectomy did not alter the contractile response to ISO. 
2. Females displayed an enhanced A1AR anti-adrenergic effect as compared to males and 
ovariectomized females, and sex differences in response to ISO were eliminated in 
A1ARKO hearts (though addition of more animals may have shown differences that were 
reduced but not eliminated). 
3. There were no sex differences in the contractile responses to AC activation, PDE inhibition, 
or stimulation of the cAMP pathway. 
4. There were no sex differences in βR or AR gene expression in ventricular myocytes. 
5. Females expressed significantly higher levels of ACV/VI in ventricular myocytes. There 
were no sex differences in the expression of Gsα protein, Gi-2α protein, PDE4D, PP1 or 
PP2A in ventricular myocytes. 
6. Females showed enhanced cAMP accumulation as compared to males, with and without 
PDE4 inhibition.   
7. There were no sex differences in the phosphorylation of TnI following ISO treatment in 
ventricular myocytes.  Females showed enhanced PLB phosphorylation following ISO 
treatment in ventricular myocytes. 
II. Sex Differences in the β-Adrenergic Contractile Response 
Results indicated that sex differences exist in β-adrenergic contractile responsiveness.  
Males exhibited enhanced contractile responses to ISO as compared to intact females.  
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Ovariectomy did not alter the βR response in females.  Males demonstrated greater vasodilation 
upon β-adrenergic receptor stimulation than intact females, possibly due to the greater increase in 
oxygen demand that accompanies greater contractile responses.   
There is some debate in the literature regarding sex differences in cardiac β-adrenergic 
receptor responsiveness.  The results of studies in rat atrial and ventricular myocytes agree with 
our findings that males show an enhanced β-adrenergic contractile response compared to females 
(Curl et al. 2001; Schwertz et al. 1999; Vizgirda et al. 2002).  In contrast, studies in isolated rat 
trabeculae (Monasky et al. 2008) and rat papillary muscle (Chu et al. 2005) indicate that no sex 
differences exist in β-adrenergic contractile responses.  These disparities may be due to 
differences in experimental models, as well as the doses of ISO used.  As shown in Figure 3, our 
studies indicated that sex differences were greater at 1 nM and 2 nM ISO.  At the high dose (10 
nM), these differences were not as dramatic.  Our study is the first in the isolated heart to show 
that sex differences exist in the β-adrenergic contractile response at low doses of ISO.  Our 
observations were made at a physiological heart rate and physiological temperature, conditions 
that were not used in previously cited studies. 
Results also indicate that ovariectomy did not alter the β-adrenergic contractile response 
in murine myocardium.  This corroborates the findings of Chu and colleagues, who found that 
ovariectomy did not change the contractile response to ISO over a wide range of doses in 
isolated rat papillary muscles (Chu et al. 2006), as well as with those of Patterson and colleagues 
using rabbit papillary muscles (Patterson et al. 1998). In contrast, Wu et al. reported that 
ovariectomy increased basal contractility and β-adrenergic contractile responses in rat ventricular 
myocytes (Wu et al. 2008).  Differences in species, age at ovariectomy, time allowed for ovarian 
withdrawal, as well as experimental model are likely to contribute to the contrasting findings. 
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III. Modulation of the βR Response by the A1 Adenosine Receptor 
The anti-adrenergic actions of adenosine are well established.  As discussed in Chapter 1, 
adenosine reduces β-adrenergic receptor-mediated increases in myocyte contractility via the 
A1AR.  The results of the present study suggest that intact females display significantly greater 
A1AR anti-adrenergic effects than males. This effect was observed in all contractile parameters 
at all doses of ISO (excluding +dP/dt at 1 nM ISO).  This is the first report to suggest that sex 
differences exist in the A1AR anti-adrenergic effect.  While β-adrenergic receptor responsiveness 
did not change following ovariectomy, the A1AR anti-adrenergic effect did appear to be 
modulated at least in part by ovarian hormones, as the enhanced anti-adrenergic effect seen in 
females was lost following ovariectomy.  Both limitation of adenylyl cyclase activity by Giα 
protein (coupled to A1AR) and activation of protein phosphatases have been implicated in the 
mechanism for the anti-adrenergic effect of adenosine (Dobson 1983; Gupta et al. 1993; Liu et al. 
2002; Narayan et al. 2000; Neumann et al. 1989; Neumann et al. 1994; Romano et al. 1990), and 
perhaps sex differences in either of these actions may contribute to the enhanced effect seen in 
intact females. 
 The observed sex differences in A1AR anti-adrenergic effect could play a role in the 
reduced β-adrenergic receptor responsiveness observed in female hearts.  There is evidence that 
endogenous adenosine, which increases in concentration during stimulation of the β-adrenergic 
receptor, acts through the A1AR to exert anti-adrenergic effects on contractility (Dobson et al. 
1986; Dobson 1996).  This serves as a negative feedback mechanism to prevent extreme 
responses to catecholamine stimulation.  Our study is the first to report the potentiation of β-
adrenergic positive inotropic responses in A1ARKO mice compared to their WT counterparts.  
As shown in Figure 5 (as compared to Figure 3), the contractile response to ISO was potentiated 
in both A1ARKO males and females compared to wild type responses.  The sex differences 
53 
 
observed in the contractile responses to ISO in wild types was eliminated in A1ARKOs, though it 
is predicted that addition of more animals would suggest that males still appear to be greater 
responders than females.  This suggests that endogenous adenosine, acting through the A1AR, 
may play a part in generating sex differences in the β-adrenergic contractile response.  However, 
it is unlikely that the A1AR is the sole mediator in generating reduced βR responsiveness in 
females, and subsequent experiments investigated other potential mechanisms in terms of the βR 
signaling pathway. 
After observing such a dramatic difference between males, intact females and 
ovariectomized females in the A1AR anti-adrenergic effect, an investigation into other roles of 
adenosine receptor function was performed.  The non-selective adenosine receptor agonist 
NECA promotes decreases in heart rate via the A1AR, as well as coronary vasodilation via the 
A2aAR and A2bAR.  In the present study, there were no sex differences in heart rate and coronary 
perfusion pressure responses to NECA, and ovarian hormone withdrawal did not alter these 
responses. 
The negative chronotropic effects of NECA are mediated by the A1AR, which slows 
atrioventricular nodal conduction.  The results of this study suggest that there are no sex 
differences in A1AR function in the conductive tissue of the heart, and this did not change in 
females following ovariectomy.  Few studies have considered sex differences in adenosine 
receptors-mediated modulation of heart rate.  In two reports, Yang and colleagues note that the 
effect of A1AR deletion on heart rate differed in males and females.  In conscious mice being 
studied using telemetry, deletion of the A1AR in females had little effect on heart rate, whereas 
males showed increases in heart rate following A1AR deletion (Yang et al. 2007; Yang et al. 
2009).  Their findings suggest that sex differences exist in the modulation heart rate by the A1AR 
when factors such as neuronal and hormonal inputs are present to modulate conduction. 
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Coronary dilatory responses were seen at doses as low as 0.5 and 1 nM NECA, with 
maximal dilation occurring at the 50 nM dose.  Dilation at lower doses of NECA is mediated by 
the high-affinity A2aAR, with dilation at higher doses of NECA being mediated by the low-
affinity A2bAR (Morrison et al. 2002).  There were no sex differences in the NECA-induced 
reductions in coronary perfusion pressure, suggesting no differences exist in A2aAR and A2bAR 
function in the coronary vasculature under normal conditions.  Few studies have considered sex 
differences in adenosine receptor function in the vasculature.  Our results correspond with the 
finding that while the mechanism of adenosine-mediated dilation in porcine coronary arterioles 
differs between males and females, their vasodilatory responses to adenosine did not (Heaps et al. 
2002). 
IV. G Protein Pathway Function in Male and Female Hearts 
 It was hypothesized that the expression and/or function of components of the G protein 
signaling pathway would differ between males and females, contributing to sex differences in the 
βR contractile response.  This study addressed the action of several components of the β-
adrenergic receptor signaling cascade in both sexes, and is the first to do so in the isolated 
perfused heart.  Since ovariectomy did not alter the βR response, this mechanistic investigation 
was not performed in ovariectomized mice.  Several investigators have used β-adrenergic 
receptor stimulation to assay cAMP accumulation, to address the possibility that myocardial 
adenylyl cyclase activity may differ between males and females (Dent et al. 2011a, Schwertz et 
al. 1999; Vizgirda et al. 2002).  However, there is discrepancy in the literature regarding the 
presence of sex differences in the expression and/or function of βR themselves.  Administration 
of forskolin specifically addresses the action of adenylyl cyclase and circumvents potential 
differences in β-adrenergic receptors which could contribute differences in cAMP accumulation.  
Our results indicate a slightly, but not significantly enhanced contractile response in males as 
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compared to females in terms of LVSP (less dramatic in both + and –dP/dt).  It is likely that 
differences would be detected with addition of more animals.  These data suggest that sex 
differences may exist in adenylyl cyclase expression and/or activity, resulting in differential 
contractile responses to forskolin, particularly at the high dose administered.  These differences 
were modest in comparison to the sex differences in the contractile response to ISO, and suggest 
that the role for adenylyl cyclase in generating this difference is, if anything, minor.  There was a 
sex effect in coronary flow responses to forskolin, with males tending to show greater 
vasodilation than females.  The cellular mechanism for adenylyl cyclase-mediated myocyte 
contraction versus adenylyl cyclase-mediated vasodilation is likely different.  It is also possible 
that adenylyl cyclase expression and/or function could differ between males and females in 
coronary vasculature, contributing to more dramatic differences observed in coronary flow 
responses than in contractile responses. 
 Another potential mechanism for the sex difference in the myocardial β-adrenergic 
receptor responsiveness could be differences in the phosphodiesterases (PDEs) which hydrolyze 
cAMP.  In dose-response studies with the non-selective PDE inhibitor IBMX, there were no 
differences in the contractile or vascular responses between male and female hearts.  There have 
been no other studies addressing potential sex-dependent differences in myocardial PDEs.  
However, Wang and colleagues noted that there were sex differences in the vascular endothelial 
cell expression of PDE1A and PDE3B genes, and males showed no functional response to 
PDE3B inhibition, while females did (Wang et al. 2010).  Another report noted that sex 
hormones modulate PDE5 gene expression and the vascular response to PDE5 inhibition (Sejima 
et al. 2009).  Our results suggest that there are no sex differences in PDE activity in the 
unstimulated heart.   
 To address if there are any sex differences in the contractile response downstream of 
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cAMP generation in the isolated heart, a non-hydrolyzable form of cAMP was administered.  
There were no sex differences in the contractile responses to CPT-cAMP.  This suggests that at 
equivalent concentrations of cAMP, males and females show similar contractile responses.  No 
known studies have considered sex differences in the activation of the myocardial protein kinase 
A signaling cascade by cAMP.  These findings suggest that one or more components acting 
upstream of the cAMP/protein kinase A phosphorylation cascade are likely responsible for the 
contractile differences between males and females in the β-adrenergic response.  Additionally, 
though not statistically significant, there was a strong tendency for males to dilate to a greater 
extent following CPT-cAMP administration as compared to females.  This suggests that in an 
otherwise unstimulated heart, downstream cAMP signaling in the vasculature may differ more 
dramatically between the sexes than in myocytes. 
V. β-Adrenergic Receptor and Adenosine Receptor Gene Expression  
It was hypothesized that observed sex differences in β-adrenergic responsiveness could 
be due to sex-dependent differences in β-adrenergic receptor expression.  However, we observed 
no sex differences in levels of either β1- or β2-adrenergic receptor gene expression in ventricular 
tissue or ventricular myocytes.  There are no other studies examining sex-dependent differences 
in β-adrenergic receptor expression in mouse myocardium. Dent and colleagues saw no 
difference in β1R or β2R gene expression in rat left ventricle, corroborating our findings in mouse 
ventricle and myocytes (Dent et al. 2011a).  Additionally, there are reports that β-adrenergic 
receptor protein expression in the rat ventricle does not differ in males and females, as 
determined by both immunoblotting (Chu et al. 2005) and radioligand binding (Dent et al. 2011).  
Interestingly, in a more recent investigation Dent et al. found females express higher levels of 
β1R protein, with no difference in mRNA, in rat left ventricle (Dent et al. 2011b).  However, this 
contrasts with other reports that males have greater β-adrenergic receptor density in rat left 
57 
 
ventricular membranes (Bordallo et al. 2009; Vizgirda et al. 2002).  Our results suggest that the 
sex differences in response to β-adrenergic receptor stimulation are not due to differences in β-
adrenergic receptor expression, at the genetic level.  However, the possibility cannot be ruled out 
that differences in β-adrenergic receptor protein expression may exist between males and females. 
Ovariectomy led to a slight reduction of ventricular β1-adrenergic receptor gene 
expression as compared to intact females, but at the level of the ventricular myocyte there were 
no differences in the level of βR expression.  Multiple studies have demonstrated that β1-
adrenergic receptor protein expression in rat ventricular membranes is increased after 
ovariectomy (Klankalya et al. 1988; Thawornkaiwong et al. 2003; Wu et al. 2008), but no known 
investigations have considered this in the mouse myocardium. Chu and colleagues showed that 
β1-adrenergic receptor protein expression increased in rat ventricle following ovariectomy, but 
this change in expression was not associated with an increase in the contractile response to ISO 
(Chu et al. 2006).  It appears that the slight decrease in cardiac β1-adrenergic receptor gene 
expression that we observed in ovariectomized mice was not at the level of the ventricular 
myocyte and had no significant functional effect in terms of the β-adrenergic contractile response. 
Females expressed a significantly higher level of the A1AR gene as compared to males in 
ventricular myocardium.  However, this difference appears to be at the level of a non-myocyte 
cell type, as no differences were seen in A1AR gene expression in ventricular myocytes.  A1AR 
gene expression was similar in ovariectomized female and male ventricular tissue, but no 
differences in A1AR gene expression were seen in intact vs. ovariectomized female myocytes.  
These results suggest that long-term exposure to ovarian hormones modulates ventricular A1AR 
gene expression in a non-myocyte cell type.  In ventricular myocytes, A3AR gene expression was 
significantly greater in intact females as compared to both males and ovariectomized females, 
but there is no known role of the A3AR in modulating the β-adrenergic receptor contractile 
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response.   
It has been demonstrated that ovarian hormone withdrawal reduced A1AR, A2aAR and 
A3AR gene expression in the rat brain (Rose’Meyer et al. 2003).  von Arnim and colleagues 
reported no gender differences in A1AR and A3AR gene expression in rat hippocampus using 
reverse transcription PCR (von Arnim et al. 2002).  There are no known investigations into 
cardiac adenosine receptor gene expression in females, or the effects of ovarian hormone 
withdrawal on cardiac AR gene expression.  Additionally, limitations in adenosine receptor 
antibodies prevented analysis of AR protein expression.  It is acknowledged that adenosine 
receptor protein expression could still differ between the groups to contribute to the observed 
differences in the A1AR anti-adrenergic effect (i.e. enhanced A1AR expression and/or reduced 
A2aAR expression in intact females). 
VI. Expression of Components of the G Protein Pathway in Myocytes 
 It was hypothesized that sex differences would exist in the expression of components of 
β-adrenergic receptor signaling pathway that would lead to reduced contractile responses in 
females (for example, enhanced Gsα protein or adenylyl cyclase in males, and/or enhanced 
phosphodiesterase or protein phosphatase expression in females).  The majority of the targets 
assessed showed no difference in expression levels between males and females.  Surprisingly, 
ventricular myocytes from females express significantly higher levels of adenylyl cyclase type 
V/VI than ventricular myocytes from males.  Dent and colleagues demonstrated no sex 
differences in adenylyl cyclase type V/VI protein or mRNA levels in rat ventricular tissue (Dent 
et al. 2011a; Dent et al. 2011b).  The expression of ACV/VI has not been investigated in male vs. 
female myocytes, nor has it been investigated in mouse myocardium in males vs. females.  While 
this was an interesting observation, it did not appear to have functional consequences in terms of 
the contractile response to forskolin.  
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 The expression of Gsα and Gi-2α proteins were no different between males and females.  
This had not previously been investigated in male vs. females in the heart.  While the possibility 
cannot be ruled out that coupling between βR and specific G proteins may differ between males 
and females, it is clear that there were no sex differences in the expression of these proteins that 
would contribute to sex differences in the response to ISO. 
 No sex differences were seen in PDE4D expression in ventricular myocytes.  As 
mentioned previously, Wang and colleagues (Wang et al. 2010) noted that there were sex 
differences in the vascular endothelial cell expression of PDE1A and PDE3B genes.  
Additionally, another report noted that sex hormones modulate PDE5 gene expression.  However, 
this is the first known investigation into sex differences in protein expression of an isoform of 
PDE, and the first to consider PDE expression in the cardiac myocyte in males vs. females.  
PDE4D, the primary form involved with regulation of the βR signaling response, did not differ in 
expression levels between males and females. 
 Expression of the two major serine/threonine protein phosphatases in the heart, PP1 and 
PP2A, was also shown to be no different between males and females.  These proteins regulate 
phosphorylation states of targets of βR signaling, and no previous studies have addressed their 
expression in both males and females.  The present findings indicate that differences in the 
expression of these two protein phosphatases do not appear to contribute to the reduced βR 
contractile response in females. 
VII. cAMP Accumulation Response to β-Adrenergic Receptor Stimulation in Myocytes 
 There was no sex difference in the basal cAMP concentration in ventricular myocytes.  
Surprisingly, females tended to demonstrate greater cAMP accumulation upon ISO treatment 
than males.  Additionally, rolipram-pretreated females showed a greater cAMP response to 10 
nM ISO than did males.  The few investigators who have considered sex differences in adenylyl 
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cyclase activity or cAMP concentration following βR stimulation have shown contrasting results.  
Schwertz and colleagues, using left atrial tissue, found no sex difference in cAMP accumulation 
following treatment with 300 nM ISO (Schwertz et al. 1999); Dent and colleagues  saw no sex 
difference in adenylyl cyclase activity following stimulation with 1 μM epinephrine in left 
ventricular tissue (though they did see reduced basal adenylyl cyclase activity in females) (Dent 
et al. 2011a).  However, Vizgirda and colleagues found that rat ventricular myocytes from males 
show a greater increase in cAMP concentration following treatment with 1 μM ISO than females 
(Vizgirda et al. 2002).  To our knowledge, no investigators have shown a greater cAMP response 
to ISO in females than in males.  However, no other group has performed these studies in mouse 
myocytes.  Additionally, we are the only group that performed these studies using lower doses of 
ISO (and the most dramatic difference appeared to be at 10 nM ISO); perhaps other groups 
would have made similar observations had they used low nM doses of ISO. 
 PDE4 inhibition with rolipram did not alter basal cAMP concentration, and it did not 
enhance the 1 nM ISO treatment.  However, cAMP concentration was significantly greater at 10 
nM ISO in cells pre-treated with rolipram as compared to control cells.  cAMP accumulation in 
response to 10 nM ISO was still greater in PDE-inhibited females as compared to PDE-inhibited 
males, suggesting that PDE activation upon βR stimulation is not responsible for the sex 
differences in the cAMP response to 10 nM ISO.  None of the aforementioned studies 
considering cAMP content in males vs. females mentioned if PDE inhibition was performed in 
their analyses.  Additionally, the phosphorylation and subsequent activation of PDE4 by PKA 
has been demonstrated in non-cardiac cells (Sette et al. 1996), but has not been assessed in 
cardiac myocytes.  The extent of PDE phosphorylation has therefore not been investigated in 
male vs. female myocytes. 
 It is possible that the enhanced adenylyl cyclase expression seen in female myocytes 
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contributed to the enhanced cAMP accumulation response following βR stimulation at the 10 nM 
dose.  Interestingly, it has been demonstrated that increased expression of adenylyl cyclase type 
VI via adenovirus in neonatal rat cardiac myocytes resulted in a proportional increase in βR 
agonist-stimulated cAMP concentration (Gao et al. 1998).  However, as previously mentioned, 
the enhanced adenylyl cyclase expression in females does not appear to have functional 
consequences at the level of the heart, as forskolin treatment showed essentially no sex 
differences in contractile responses.  The mechanism for the enhanced cAMP response to ISO in 
females at 10 nM ISO remains unclear. 
VIII. Phosphorylation of TnI and PLB following β-Adrenergic Receptor Stimulation in 
Myocytes 
 There were no sex differences in the basal level of troponin I or phospholamban 
phosphorylation between males and females.  Additionally, there were no differences in TnI 
phosphorylation following 10 minutes of treatment with 10 or 100 nM ISO.  Surprisingly, 
females showed enhanced phospholamban phosphorylation as compared to males at 100 nM ISO. 
 PKA-mediated phosphorylation of both troponin I and phospholamban is involved in the 
positive lusitropic response elicited by β-adrenergic receptor stimulation.  There is some 
controversy over the extent that these proteins play in enhancing the rate of myocyte relaxation 
during βR stimulation (though these studies have been performed only in males).  The 
importance of phospholamban in regulating calcium reuptake into the sarcoplasmic reticulum 
and promoting relaxation is clear.  It has been suggested that the role of TnI in promoting 
relaxation via decreasing troponin sensitivity to calcium is less significant than that of PLB but 
still important (Li et al. 2000).  However, multiple groups have demonstrated that both PLB and 
TnI phosphorylation play important roles in the lusitropic effects of ISO (Kentish et al. 2001; 
Wolska et al. 2002; Yasuda et al. 2007), including a recent study demonstrating synergistic 
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effects of TnI and PLB phosphorylation in promoting relaxation (Zhang et al. 2011). 
 It was hypothesized that females would show reduced phosphorylation states of the 
targets of βR signaling, such as troponin I and phospholamban.  Pott and colleagues showed no 
differences in basal TnI phosphorylation states between murine males and females (Pott et al. 
2008).  Interestingly, Zhong et al. demonstrated no sex difference in basal phosphorylation of 
PLB at residue serine 16, but the reduction in PLB phosphorylation that accompanies diabetes 
was less pronounced in females than males (Zhong et al. 2003).  However, to our knowledge, no 
one has investigated βR signaling at the level of phosphorylation of these proteins in both males 
and females. 
 It is unclear why females would show an enhanced phosphorylation response in PLB but 
not TnI, as these proteins are phosphorylated by the same kinase and regulated by the same 
phosphatases (Sulakhe et al. 1995).  A kinase anchoring proteins (AKAPs) are involved in the 
spatiotemporal modulation of signaling in the cardiac myocyte, serving as an integration site for 
PKA with other kinase-mediated signaling pathways.  TnI and PLB phosphorylation events are 
controlled in part by the action of AKAPs (Fink et al. 2001), and no studies into sex differences 
in AKAP function have been performed.  Studies into the regulation of PLB and TnI 
phosphorylation have been performed only in males, and it is possible that differences in the 
regulation of signaling between males and females could lead to this differential phosphorylation 
response.  Additionally, PLB and p-PLB were detected primarily in the monomeric form, but is 
likely to exist in native SR membranes primarily in the pentameric form (Sulakhe et al. 1995), 
and it is possible that the phosphorylation response to ISO may differ in monomeric vs. 
pentameric PLB. 
IX. Limitations 
 A robust analysis of the β-adrenergic receptor contractile response and signaling cascade 
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in males and females was performed in this project.  There are limitations to the studies that were 
performed, and these limitations are listed below.  
1. It is possible that a physiological disconnect exists between the results seen in an intact, 
beating heart and quiescent, freshly isolated ventricular myocytes.  It was predicted that a 
mechanism for sex differences in the βR contractile response would be found at the level 
of the myocyte, as this is the cell type responsible for contractile events.  However, a 
change in physiological properties in myocytes between intact myocardium and freshly 
isolated myocyte may have prevented those differences from being observed.  
Additionally, involvement of other cell types in the contractile effects seen in the isolated 
heart cannot be ignored. 
2. It is well-accepted that cAMP signaling, such as that which occurs during βR signaling, is 
highly compartmentalized in the cell.  The technique used to quantify cAMP 
concentration in a cell lysate may have overlooked sex differences in cAMP 
compartmentalization. 
3. Determining the expression of β1R and β2R, as well as the A1AR and A2aAR protein, 
would be highly informative for this study.  As mentioned previously, serious limitations 
in specificity of the antibodies prevented their use in the study.  While speculation on 
expression levels may be made using Real Time PCR, gene and protein expression trends 
do not always coincide, and knowledge of the level of protein would be helpful in 
interpreting these data. 
4. ISO is a non-selective β-adrenergic receptor agonist.  Both β1R and β2R are capable of 
altering cardiac contractility, but differ in their signaling, regulation and extent of 
compartmentalization of signaling.  To thoroughly address sex differences in the βR 
contractile response, studies would also have to be performed using ISO in the presence 
64 
 
of selective β1R and β2R antagonists. 
X. Summary, Conclusions and Future Directions 
 The primary hypothesis of this study, that females display a reduced contractile response 
to β-adrenergic receptor stimulation as compared to males in the isolated heart, was supported.  
Ovarian hormone withdrawal did not alter this response in females.  The secondary hypothesis of 
this study was that females would show altered expression and/or function in components of the 
β-adrenergic receptor signaling pathway which would contribute to this response.  However, this 
was not supported, and the mechanism for the reduced response to ISO in females remains 
unclear.  Rather, females appear to show a compensatory response to reduced βR responsiveness 
in isolated myocytes: increased expression of adenylyl cyclase type V/VI, enhanced cAMP 
accumulation upon ISO treatment, and enhanced phospholamban phosphorylation.   
 It is possible that sex differences in the response to ISO occur due to differential 
regulation of calcium in male versus female ventricular myocytes. Chu et al. demonstrated that 
females express higher levels of Cav1.2, ryanodine receptor and sodium-calcium exchanger in 
rat ventricle, all proteins involved in calcium regulation (Chu et al. 2005).  Others have shown 
reduced amplitudes of calcium transients under both basal and ISO-stimulated conditions in 
females (Chen et al. 2003; Farrell et al. 2010; Wasserstrom et al. 2008).  Indeed, Chen and 
colleagues demonstrated that females show reduced sarcoplasmic reticulum calcium loading 
after treating rat ventricular myocytes with ISO, which they attribute to greater nitric oxide 
generation in females as compared to males (Chen et al. 2003).  Our finding that PLB 
phosphorylation is enhanced in females does not support these conclusions, but species 
differences as well as dose and timing of ISO treatment may contribute to this disagreement.  
 It is likely that the mechanism for reduced β-adrenergic receptor contractile responses in 
female hearts is multifaceted.  Future studies should address the ideas of differential contribution 
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of β1R vs. β2R to the response to non-selective agonist ISO in males and females, as well as how 
cAMP signaling and calcium transients which occur when these receptors are stimulated differ 
between males and females.  Additionally, the studies that were performed in ventricular 
myocytes should also be performed in ventricular tissue, to address the possibility that changes 
in physiology that occur during and following myocyte isolation may have altered βR responses.  
For example, it would be predicted that phospholamban phosphorylation would be enhanced in 
males upon ISO treatment in the ventricle, which would be necessary for enhanced relaxation in 
males as compared to females, but this wasn’t detected in myocytes.  Finally, the possibility that 
other cell types may contribute to the observations made in the ventricle, such as vascular 
endothelial cells, should not be ignored.  These cells express both βRs and ARs, and co-culture 
studies using ventricular myocytes and endothelial cells could address if interactions between 
cell types contribute to differential responses to ISO in the heart.   
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 Premenopausal females are at a reduced risk for developing cardiovascular disease as 
compared to males; this sex difference is not present following menopause.  β-adrenergic 
receptors are pharmaceutical targets in the treatment of cardiovascular disease, and sex 
differences in β-adrenergic responsiveness have been demonstrated.  However, limited studies 
have addressed the mechanism(s) underlying these differences.  To investigate these sex 
differences, studies were performed using isolated perfused hearts from male, intact female and 
ovariectomized female mice, as well as male and female ventricular myocytes.  Female hearts 
exhibited blunted contractile responses to the β-adrenergic receptor agonist isoproterenol (ISO) 
compared to males but not ovariectomized females.  The role of the A1 adenosine receptor 
(A1AR) in antagonizing the β-adrenergic contractile response was investigated using the A1AR 
agonist CCPA and A1AR knockout (KO) mice.  Intact females showed an enhanced A1AR anti-
adrenergic effect compared to males and ovariectomized females.  The β-adrenergic contractile 
response was potentiated in male and female A1ARKO hearts, with sex differences no longer 
present. Forskolin (FSK), IBMX and CPT-cAMP dose response studies were performed in the 
isolated heart to investigate the role of adenylyl cyclase, phosphodiesterase and the cAMP 
signaling cascade, respectively, in generating sex differences in the β-adrenergic contractile 
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response. There were essentially no sex differences in the contractile responses to FSK, IBMX or 
CPT-cAMP.  There were no sex differences in the expression of the β1R, β2R, or A1AR gene in 
ventricular myocytes, nor were there differences in the expression of Gsα protein, Gi-2α protein, 
PDE4D, PP1 or PP2A as determined with western blotting.  Adenylyl cyclase V/VI was 
expressed in significantly higher levels in female myocytes.  Females showed enhanced cAMP 
accumulation upon ISO treatment with and without PDE4 inhibition.  No sex differences were 
present in troponin I phosphorylation at 10 or 100 nM ISO, while females displayed enhanced 
phospholamban phosphorylation only at 100 nM ISO.  Females appear to show compensatory 
increases in adenylyl cyclase expression, cAMP accumulation and phospholamban 
phosphorylation.  The mechanism(s) for the reduced β-adrenergic contractile response in female 
hearts remains unresolved. 
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